TIE ligands

ABSTRACT

The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5 and NL8, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.

FIELD OF THE INVENTION

[0001] The present invention concerns isolated nucleic acid moleculesencoding novel TIE ligands, the TIE proteins encoded by such nucleicacid molecules, as well as methods and means for making and using suchnucleic acid and protein molecules.

[0002] Background Art

[0003] The abbreviations “TIE” or “tie” are acronyms, which stand for“tyrosine kinase containing Ig and EGF homology domains” and were coinedto designate a new family of receptor tyrosine kinases which are almostexclusively expressed in vascular endothelial cells and earlyhemopoietic cells, and are characterized by the presence of an EGF-likedomain, and extracellular folding units stabilized by intra-chaindisulfide bonds, generally referred to as “immunoglobulin (IG)-like”folds. A tyrosine kinase homologous cDNA fragment from human leukemiacells (tie) was described by Partanen et al., Proc. Natl. Acad. Sci. USA87, 8913-8917 (1990). The mRNA of this human “tie” receptor has beendetected in all human fetal and mouse embryonic tissues, and has beenreported to be localized in the cardiac and vascular endothelial cells.Korhonen et al., Blood 80, 2548-2555 (1992); PCT Application PublicationNo. WO 93/14124 (published Jul. 22, 1993). The rat homolog of human tie,referred to as “tie-1”, was identified by Maisonpierre et al., Oncogene8, 1631-1637 (1993)). Another tie receptor, designated “tie-2” wasoriginally identified in rats (Dumont et al., Oncogene 8, 1293-1301(1993)), while the human homolog of tie-2, referred to as “ork” wasdescribed in U.S. Pat. No. 5,447,860 (Ziegler). The murine homolog oftie-2 was originally termed “tek.” The cloning of a mouse tie-2 receptorfrom a brain capillary cDNA library is disclosed in PCT ApplicationPublication No. WO 95/13387 (published May 18, 1995). The TIE receptorsare believed to be actively involved in angiogenesis, and may play-arole in hemopoiesis as well.

[0004] The expression cloning of human TIE-2 ligands has been describedin PCT Application Publication No. WO 96/11269 (published Apr. 18, 1996)and in U.S. Pat. No. 5,521,073 (published May 28, 1996). A vectordesignated as λgt10 encoding a TIE-2 ligand named “htie-2 ligand 1” or“hTL1” has been deposited under ATCC Accession No. 75928. A plasmidencoding another TIE-2 ligand designated “htie-2 2” or “hTL2” isavailable under ATCC Accession No. 75928. This second ligand has beendescribed as an antagonist of the TAI-2 receptor. The identification ofsecreted human and mouse ligands for the TIE-2 receptor has beenreported by Davis et al., Cell 87, 1161-1169 (1996). The human liganddesignated “Angiopoietin-1”, to reflect its role in angiogenesis andpotential action during hemopoiesis, is the same ligand as the ligandvariously designated as “htie-2 1 or “hTL-1” in WO 96/11269.Angiopoietin-1 has been described to play an angiogenic role later anddistinct from that of VEGF (Suri et al., Cell 87, 1171-1180 (1996)).Since TIE-2 is apparently upregulated during the pathologic angiogenesisrequisite for tumor growth (Kaipainen et al., Cancer Res. 54, 6571-6577(1994)) angiopoietin-1 has been suggested to be additionally useful forspecifically targeting tumor vasculature (Davis et al., supra).

SUMMARY OF THE INVENTION

[0005] The present invention concerns novel human TIE ligands withpowerful effects on vasculature. The invention also provides forisolated nucleic acid molecules encoding such ligands or functionalderivatives thereof, and vectors containing such nucleic acid molecules.The invention further concerns host cells transformed with such nucleicacid to produce the novel TIE ligands or functional derivatives thereof.The novel ligands may be agonists or antagonists of TIE receptors, knownor hereinafter discovered. Their therapeutic or diagnostic use,including the delivery of other therapeutic or diagnostic agents tocells expressing the respective TIE receptors, is also within the scopeof the present invention.

[0006] The present invention further provides for agonist or antagonistantibodies specifically binding the TIE ligands herein, and thediagnostic or therapeutic use of such antibodies.

[0007] In another aspect, the invention concerns compositions comprisingthe novel ligands or antibodies.

[0008] In a further aspect, the invention concerns conjugates of thenovel TIE ligands of the present invention with other therapeutic orcytotoxic agents, and compositions comprising such conjugates. Becausethe TIE-2 receptor has been reported to be upregulated during thepathologic angiogenesis that is requisite for tumor growth, theconjugates of the TIE ligands of the present invention to cytotoxic orother anti-tumor agents are useful in specifically targeting tumorvasculature.

[0009] In yet another aspect, the invention concerns a method foridentifying a cell that expresses a TIE (e.g. TIE-2) receptor, whichcomprises contacting a cell with a detectably labeled TIE ligand of thepresent invention under conditions permitting the binding of such TIEligand to the TIE receptor, and determining whether such binding hasindeed occurred.

[0010] In a different aspect, the invention concerns a method formeasuring the amount of a TIE ligand of the present invention in abiological sample by contacting the biological sample with at least oneantibody specifically binding the TIE ligand, and measuring the amountof the TIE ligand-antibody complex formed.

[0011] The invention further concerns a screening method for identifyingpolypeptide or small molecule agonists or antagonists of a TIE receptorbased upon their ability to compete with a native or variant TIE ligandof the present invention for binding to a corresponding TIE receptor.

[0012] The invention also concerns a method for imaging the presence ofangiogenesis in wound healing, in inflammation or in tumors of humanpatients, which comprises administering detectably labeled TIE ligandsor agonist antibodies of the present invention, and detectingangiogenesis.

[0013] In another aspect, the invention concerns a method of promotingor inhibiting neovascularization in a patient by administering aneffective amount of a TIE ligand of the present invention in apharmaceutically acceptable vehicle. In a preferred embodiment, thepresent invention concerns a method for the promotion of wound healing.In another embodiment, the invention concerns a method for promotingangiogenic processes, such as for inducing collateral vascularization inan ischemic heart or limb. In a further preferred embodiment, theinvention concerns a method for inhibiting tumor growth.

[0014] In yet another aspect, the invention concerns a method ofpromoting bone development and/or maturation and/or growth in a patient,comprising administering to the patient an effective amount of a TIEligand of the present invention in a pharmaceutically acceptablevehicle.

[0015] In a further aspect, the invention concerns a method of promotingmuscle growth and development, which comprises administering a patientin need an effective amount of a TIE ligand of the present invention ina pharmaceutically acceptable vehicle.

[0016] The TIE ligands of the present invention may be administeredalone, or in combination with each other and/or with other therapeuticor diagnostic agents, including members of the VEGF family. Combinationstherapies may lead to new approaches for promoting or inhibitingneovascularization, and muscle growth and development.

BRIEF DESCRIPTION OF THE FIGURES

[0017]FIG. 1-A is the nucleotide sequence of FLS139 (SEQ. ID. NO.: 16).

[0018]FIG. 1-B is the amino acid sequence of FLS139 (SEQ. ID. NO.: 17).

[0019]FIG. 2 is the nucleotide sequence of the TIE ligand NL1 (SEQ. ID.NO: 1) (DNA 22779).

[0020]FIG. 3 is the amino acid sequence of the TIE ligand NL1 (SEQ. ID.NO:2).

[0021]FIG. 4 is the nucleotide sequence of the TIE ligand NL5 (SEQ. ID.NO: 3) (DNA 28497).

[0022]FIG. 5 is the amino acid sequence of the TIE ligand NL5 (SEQ. ID.NO: 4).

[0023]FIG. 6 is the nucleotide sequence of the TIE ligand NL8 (SEQ. IDNO: 5) (DNA 23339).

[0024]FIG. 7 is the amino acid sequence of the TIE ligand NL8 (SEQ. IDNO:6).

[0025] FIGS. 8-A and 8-B show the expression of NL1 in various tissuesas determined by in situ hybridization to cellular RNA.

[0026] FIGS. 9-A and 9-B show the expression of NL5 in various tissuesas determined by in situ hybridization to cellular RNA.

[0027] FIGS. 10-A and 10-B show the expression of NL8 in various tissuesas determined by in situ hyridization to cellular RNA.

[0028]FIGS. 11 and 12—Northern blots showing the expression of the mRNAsof TIE ligands NL1 and NL5 in various tissues.

DETAILED DESCRIPTION OF THE INVENTION

[0029] A. Tie Ligands and Nucleic Acid Molecules Encoding Them

[0030] The TIE ligands of the present invention include the native humanligands designated NL1 (SEQ. ID. NO: 2), NL5 (SEQ. ID. NO: 4), and NL8(SEQ. ID. NO: 6), their homologs in other, non-human mammalian species,including, but not limited to, higher mammals, such as monkey; rodents,such as mice, rats, hamster; porcine; equine; bovine; naturallyoccurring allelic and splice variants, and biologically active(functional) derivatives, such as, amino acid sequence variants of suchnative molecules, as long as they differ from a native TL-1 or TL-2ligand. The native TIE ligands of the present invention aresubstantially free of other proteins with which they are associated intheir native environment. This definition is not limited in any way bythe method(s) by which the TIE ligands of the present invention areobtained, and includes all ligands otherwise within the definition,whether purified from natural source, obtained by recombinant DNAtechnology, synthesized, or prepared by any combination of these and/orother techniques. The amino acid sequence variants of the native TIEligands of the present invention shall have at least about 90%,preferably, at least about 95%, more preferably at least about 98%, mostpreferably at least about 99% sequence identity with a full-length,native human TIE ligand of the present invention, or with thefibrinogen-like domain of a native human TIE ligand of the presentinvention. Such amino acid sequence variants preferably exhibit orinhibit a qualitative biological activity of a native TIE ligand.

[0031] The term “fibrinogen domain” or “fibrinogen-like domain” is usedto refer to amino acids from about position 278 to about position 498 inthe known hTL-1 amino acid sequence; amino acids from about position 276to about position 496 in the known hTL-2 amino acid sequence; aminoacids from about position 270 to about 493 in the amino acid sequence ofNL1; amino acids from about position 272 to about position 491 in theamino acid sequence of NL5; and amino acids from about position 252 toabout position 470 in the amino acid sequence of NL8; and to homologousdomains in other TIE ligands.

[0032] The term “nucleic acid molecule” includes RNA, DNA and cDNAmolecules. It will be understood that, as a result of the degeneracy ofthe genetic code, a multitude of nucleotide sequences encoding a givenTIE ligand may be produced. The present invention specificallycontemplates every possible variation of nucleotide sequences, encodingthe TIE ligands of the present invention, based upon all possible codonchoices. Although nucleic acid molecules which encode the TIE ligandsherein are preferably capable of hybridizing, under stringentconditions, to a naturally occurring TIE ligand gene, it may beadvantageous to produce nucleotide sequences encoding TIE ligands, whichpossess a substantially different codon usage. For example, codons maybe selected to increase the rate at which expression of the polypeptideoccurs in a particular prokaryotic or eukaryotic host cells, inaccordance with the frequency with which a particular codon is utilizedby the host. In addition, RNA transcripts with improved properties, e.g.half-life can be produced by proper choice of the nucleotide sequencesencoding a given TIE ligand.

[0033] “Sequence identity” shall be determined by aligning the twosequences to be compared following the Clustal method of multiplesequence alignment (Higgins et al., Comput. Appl. Biosci. 5, 151-153(1989), and Higgins et al., Gene 73, 237-244 (1988)) that isincorporated in version 1.6 of the Lasergene biocomputing software(DNASTAR, Inc., Madison, Wis.), or any updated version or equivalent ofthis software.

[0034] The terms “biological activity” and “biologically active” withregard to a TIE ligand of the present invention refer to the ability ofa molecule to specifically bind to and signal through a native TIEreceptor, e.g. a native TIE-2 receptor, or to block the ability of anative TIE receptor (e.g. TIE-2) to participate in signal transduction.Thus, the (native and variant) TIE ligands of the present inventioninclude agonists and antagonists of a native TIE, e.g. TIE-2, receptor.Preferred biological activities of the TIE ligands of the presentinvention include the ability to induce or inhibit vascularization. Theability to induce vascularization will be useful for the treatment ofbiological conditions and diseases, where vascularization is desirable,such as wound healing, ischaemia, and diabetes. On the other hand, theability to inhibit or block vascularization may, for example, be usefulin preventing or attenuating tumor growth. Another preferred biologicalactivity is the ability to affect muscle growth or development. Afurther preferred biological activity is the ability to influence bonedevelopment, maturation, or growth.

[0035] The term “functional derivative” is used to define biologicallyactive amino acid sequence variants of the native TIE ligands of thepresent invention, as well as covalent modifications, includingderivatives obtained by reaction with organic derivatizing agents,post-translational modifications, derivatives with nonproteinaceouspolymers, and immunoadhesins.

[0036] “Vascular endothelial growth factor”/“vascular permeabilityfactor” (VEGF/VPF) is an endothelial cell-specific mitogen which hasrecently been shown to be stimulated by hypoxia and required for tumorangiogenesis (Senger et al., Cancer 46: 5629-5632 (1986); Kim et al.,Nature 362:841-844 (1993); Schweiki et al., Nature 359: 843-845 (1992);Plate et al., Nature 359: 845-848 (1992)). It is a 34-43 kDa (with thepredominant species at about 45 kDa) dimeric, disulfide-linkedglycoprotein synthesized and secreted by a variety of tumor and normalcells. In addition, cultured human retinal cells such as pigmentepithelial cells and pericytes have been demonstrated to secrete VEGFand to increase VEGF gene expression in response to hypoxia (Adamis etal., Biochem. Biophys. Res. Commun. 193: 631-638 (1993); Plouet et al.,Invest. Ophthalmol. Vis. Sci. 34: 900 (1992); Adamis et al., Invest.Ophthalmol. Vis. Sci. 34: 1440 (1993); Aiello et al., Invest. Opthalmol.Vis. Sci. 35: 1868 (1994); Simorre-pinatel et al., Invest. Opthalmol.Vis. Sci. 35: 3393-3400 (1994)). In contrast, VEGF in normal tissues isrelatively low. Thus, VEGF appears to play a principle role in manypathological states and processes related to neovascularization.Regulation of VEGF expression in tissues affected by the variousconditions described above could therefore be key in treatment orpreventative therapies associated with hypoxia.

[0037] The term “isolated” when used to describe the variouspolypeptides described herein, means polypeptides that have beenidentified and separated and/or recovered from a component of itsnatural environment. Contaminant components of its natural environmentare materials that would typically interfere with diagnostic ortherapeutic uses for the polypeptide, and may include enzymes, hormones,and other proteinaceous or non-proteinaceous solutes. In preferredembodiments, the polypeptide will be purified (1) to a degree sufficientto obtain at least 15 residues of N-terminal or internal amino acidsequence by use of a spinning cup sequenator, or (2) to homogeneity bySDS-PAGE under non-reducing or reducing conditions using Coomassie blueor, preferably, silver stain. Isolated polypeptide includes polypeptidein situ within recombinant cells, since at least one component of theTIE ligand's natural environment will not be present. Ordinarily,however, isolated polypeptide will be prepared by at least onepurification step.

[0038] An “isolated” nucleic acid molecule is a nucleic acid moleculethat is identified and separated from at least one contaminant nucleicacid molecule with which it is ordinarily associated in the naturalsource of the nucleic acid. An isolated nucleic acid molecule is otherthan in the form or setting in which it is found in nature. Isolatednucleic acid molecules therefore are distinguished from the nucleic acidmolecule as it exists in natural cells. However, an isolated nucleicacid molecule includes nucleic acid molecules contained in cells thatordinarily express an TIE ligand of the present invention, where, forexample, the nucleic acid molecule is in a chromosomal locationdifferent from that of natural cells.

[0039] The term “amino acid sequence variant” refers to molecules withsome differences in their amino acid sequences as compared to a nativeamino acid sequence.

[0040] Substitutional variants are those that have at least one aminoacid residue in a native sequence removed and a different amino acidinserted in its place at the same position. The substitutions may besingle, where only one amino acid in the molecule has been substituted,or they may be multiple, where two or more amino acids have beensubstituted in the same molecule.

[0041] Insertional variants are those with one or more amino acidsinserted immediately adjacent to an amino acid at a particular positionin a native sequence. Immediately adjacent to an amino acid meansconnected to either the α-carboxy or α-amino functional group of theamino acid.

[0042] Deletional variants are those with one or more amino acids in thenative amino acid sequence removed. Ordinarily, deletional variants willhave one or two amino acids deleted in a particular region of themolecule. Deletional variants include those having C- and/or N-terminaldeletions (truncations) as well as variants with internal deletions ofone or more amino acids. The preferred deletional variants of thepresent invention contain deletions outside the fibrinogen-like domainof a native TIE ligand of the present invention.

[0043] The amino acid sequence variants of the present invention maycontain various combinations of amino acid substitutions, insertionsand/or deletions, to produce molecules with optimal characteristics.

[0044] The amino acids may be classified according to the chemicalcomposition and properties of their side chains. They are broadlyclassified into two groups, charged and uncharged. Each of these groupsis divided into subgroups to classify the amino acids more accurately.

[0045] I. Charged Amino Acids

[0046] Acidic Residues: aspartic acid, glutamic acid

[0047] Basic Residues: lysine, arginine, histidine

[0048] II. Uncharged Amino Acids

[0049] Hydrophilic Residues: serine, threonine, asparagine, glutamine

[0050] Aliphatic Residues: glycine, alanine, valine, leucine, isoleucine

[0051] Non-polar Residues: cysteine, methionine, proline

[0052] Aromatic Residues: phenylalanine, tyrosine, tryptophan

[0053] Conservative substitutions involve exchanging a member within onegroup for another member within the same group, whereas non-conservativesubstitutions will entail exchanging a member of one of these classesfor another. Variants obtained by non-conservative substitutions areexpected to result in significant changes in the biologicalproperties/function of the obtained variant

[0054] Amino acid sequence deletions generally range from about 1 to 30residues, more preferably about 1 to 10 residues, and typically arecontiguous. Deletions may be introduced into regions not directlyinvolved in the interaction with a native TIE receptor. Deletions arepreferably performed outside the fibrinogen-like regions at theC-terminus of the TIE ligands of the present invention.

[0055] Amino acid insertions include amino- and/or carboxyl-terminalfusions ranging in length from one residue to polypeptides containing ahundred or more residues, as well as intrasequence insertions of singleor multiple amino acid residues. Intrasequence insertions (i.e.insertions within the TIE ligand amino acid sequence) may rangegenerally from about 1 to 10 residues, more preferably 1 to 5 residues,more preferably 1 to 3 residues. Examples of terminal insertions includethe TIE ligands with an N-terminal methionyl residue, an artifact of itsdirect expression in bacterial recombinant cell culture, and fusion of aheterologous N-terminal signal sequence to the N-terminus of the TIEligand molecule to facilitate the secretion of the mature TIE ligandfrom recombinant host cells. Such signal sequences will generally beobtained from, and thus homologous to, the intended host cell species.Suitable sequences include, for example, STII or Ipp for E. coli, alphafactor for yeast, and viral signals such as herpes gD for mammaliancells. Other insertional variants of the native TIE ligand moleculesinclude the fusion of the N- or C-terminus of the TIE ligand molecule toimmunogenic polypeptides, e.g. bacterial polypeptides such asbeta-lactamase or an enzyme encoded by the E. coli trp locus, or yeastprotein, and C-terminal fusions with proteins having a long half-lifesuch as immunoglobulin regions (preferably immunoglobulin constantregions), albumin, or ferritin, as described in WO 89/02922 published onApr. 6, 1989.

[0056] Since it is often difficult to predict in advance thecharacteristics of a variant TIE ligand, it will be appreciated thatsome screening will be needed to select the optimum variant.

[0057] Amino acid sequence variants of native TIE ligands of the presentinvention are prepared by methods known in the art by introducingappropriate nucleotide changes into a native or variant TIE ligand DNA,or by in vitro synthesis of the desired polypeptide. There are twoprincipal variables in the construction of amino acid sequence variants:the location of the mutation site and the nature of the mutation. Withthe exception of naturally-occurring alleles, which do not require themanipulation of the DNA sequence encoding the TIE ligand, the amino acidsequence variants of TIE are preferably constructed by mutating the DNA,either to arrive at an allele or an amino acid sequence variant thatdoes not occur in nature.

[0058] One group of the mutations will be created within the domain ordomains of the TIE ligands of the present invention identified as beinginvolved in the interaction with a TIE receptor, e.g. TIE-1 or TIE-2.

[0059] Alternatively or in addition, amino acid alterations can be madeat sites that differ in TIE ligands from various species, or in highlyconserved regions, depending on the goal to be achieved.

[0060] Sites at such locations will typically be modified in series,e.g. by (1) substituting first with conservative choices and then withmore radical selections depending upon the results achieved, (2)deleting the target residue or residues, or (3) inserting residues ofthe same or different class adjacent to the located site, orcombinations of options 1-3.

[0061] One helpful technique is called “alanine scanning” (Cunninghamand Wells, Science 244, 1081-1085 [1989]). Here, a residue or group oftarget residues is identified and substituted by alanine or polyalanine.Those domains demonstrating functional sensitivity to the alaninesubstitutions are then refined by introducing further or othersubstituents at or for the sites of alanine substitution.

[0062] After identifying the desired mutation(s), the gene encoding anamino acid sequence variant of a TIE ligand can, for example, beobtained by chemical synthesis as hereinabove described.

[0063] More preferably, DNA encoding a TIE ligand amino acid sequencevariant is prepared by site-directed mutagenesis of DNA that encodes anearlier prepared variant or a nonvariant version of the ligand.Site-directed (site-specific) mutagenesis allows the, production ofligand variants through the use of specific oligonucleotide sequencesthat encode the DNA sequence of the desired mutation, as well as asufficient number of adjacent nucleotides, to provide a primer sequenceof sufficient size and sequence complexity to form a stable duplex onboth sides of the deletion junction being traversed. Typically, a primerof about 20 to 25 nucleotides in length is preferred, with about 5 to 10residues on both sides of the junction of the sequence being altered. Ingeneral, the techniques of site-specific mutagenesis are well known inthe art, as exemplified by publications such as, Edelman et al., DNA 2,183 (1983). As will be appreciated, the site-specific mutagenesistechnique typically employs a phage vector that exists in both asingle-stranded and double-stranded form. Typical vectors useful insite-directed mutagenesis include vectors such as the M13 phage, forexample, as disclosed by Messing et al., Third Cleveland Symposium onMacromolecules and Recombinant DNA, A. Walton, ed., Elsevier, Amsterdam(1981). This and other phage vectors are commercially available andtheir use is well known to those skilled in the art. A versatile andefficient procedure for the construction of oligodeoxyribonucleotidedirected site-specific mutations in DNA fragments using M13-derivedvectors was published by Zoller, M. J. and Smith, M., Nucleic Acids Res.10, 6487-6500 [1982]). Also, plasmid vectors that contain asingle-stranded phage origin of replication (Veira et al., Meth. Enzymol153, 3 [1987]) may be employed to obtain single-stranded DNA.Alternatively, nucleotide substitutions are introduced by synthesizingthe appropriate DNA fragment in vitro, and amplifying it by PCRprocedures known in the art.

[0064] In general, site-specific mutagenesis herewith is performed byfirst obtaining a single-stranded vector that includes within itssequence a DNA sequence that encodes the relevant protein. Anoligonucleotide primer bearing the desired mutated sequence is prepared,generally synthetically, for example, by the method of Crea et al.,Proc. Natl. Acad. Sci. USA 75, 5765 (1978). This primer is then annealedwith the single-stranded protein sequence-containing vector, andsubjected to DNA-polymerizing enzymes such as, E. coli polymerase IKlenow fragment, to complete the synthesis of the mutation-bearingstrand. Thus, a heteroduplex is formed wherein one strand encodes theoriginal non-mutated sequence and the second strand bears the desiredmutation. This heteroduplex vector is then used to transform appropriatehost cells such as JP101 cells, and clones are selected that includerecombinant vectors bearing the mutated sequence arrangement.Thereafter, the mutated region may be removed and placed in anappropriate expression vector for protein production.

[0065] The PCR technique may also be used in creating amino acidsequence variants of a TIE ligand. When small amounts of template DNAare used as starting material in a PCR, primers that differ slightly insequence from the corresponding region in a template DNA can be used togenerate relatively large quantities of a specific DNA fragment thatdiffers from the template sequence only at the positions where theprimers differ from the template. For introduction of a mutation into aplasmid DNA, one of the primers is designed to overlap the position ofthe mutation and to contain the mutation; the sequence of the otherprimer must be identical to a stretch of sequence of the opposite strandof the plasmid, but this sequence can be located anywhere along theplasmid DNA. It is preferred, however, that the sequence of the secondprimer is located within 200 nucleotides from that of the first, suchthat in the end the entire amplified region of DNA bounded by theprimers can be easily sequenced. PCR amplification using a primer pairlike the one just described results in a population of DNA fragmentsthat differ at the position of the mutation specified by the primer, andpossibly at other positions, as template copying is somewhaterror-prone.

[0066] If the ratio of template to product material is extremely low,the vast majority of product DNA fragments incorporate the desiredmutation(s). This product material is used to replace the correspondingregion in the plasmid that served as PCR template using standard DNAtechnology. Mutations at separate positions can be introducedsimultaneously by either using a mutant second primer or performing asecond PCR with different mutant primers and ligating the two resultingPCR fragments simultaneously to the vector fragment in a three (or more)part ligation.

[0067] In a specific example of PCR mutagenesis, template plasmid DNA (1μg) is linearized by digestion with a restriction endonuclease that hasa unique recognition site in the plasmid DNA outside of the region to beamplified. Of this material, 100 ng is added to a PCR mixture containingPCR buffer, which contains the four deoxynucleotide triphosphates and isincluded in the GeneAmp^(R) kits (obtained from Perkin-Elmer Cetus,Norwalk, Conn. and Emeryville, Calif.), and 25 pmole of eacholigonucleotide primer, to a final volume of 50 μl. The reaction mixtureis overlayered with 35 μl mineral oil. The reaction is denatured for 5minutes at 100° C., placed briefly on ice, and then 1 μl Thermusaquaticus (Taq) DNA polymerase (5 units/l), purchased from Perkin-ElmerCetus, Norwalk, Conn. and Emeryville, Calif.) is added below the mineraloil layer. The reaction mixture is then inserted into a DNA ThermalCycler (purchased from Perkin-Elmer Cetus) programmed as follows:

[0068] 2 min. 55° C.,

[0069] 30 sec. 72° C., then 19 cycles of the following:

[0070] 30 sec. 94° C.,

[0071] 30 sec. 55° C., and

[0072] 30 sec. 72° C.

[0073] At the end of the program, the reaction vial is removed from thethermal cycler and the aqueous phase transferred to a new vial,extracted with phenol/chloroform (50:50 vol), and ethanol precipitated,and the DNA is recovered by standard procedures. This material issubsequently subjected to appropriate treatments for insertion into avector.

[0074] Another method for preparing variants, cassette mutagenesis, isbased on the technique described by Wells et al. [Gene 34, 315 (1985)].The starting material is the plasmid (or vector) comprising the TIEligand DNA to be mutated. The codon(s) within the TIE ligand to bemutated are identified. There must be a unique restriction endonucleasesite on each side of the identified mutation site(s). If no suchrestriction sites exist, they may be generated using the above-describedoligonucleotide-mediated mutagenesis method to introduce them atappropriate locations in the DNA encoding the TIE ligand. After therestriction sites have been introduced into the plasmid, the plasmid iscut at these sites to linearize it. A double-stranded oligonucleotideencoding the sequence of the DNA between the restriction site butcontaining the desired mutation(s) is synthesized using standardprocedures. The two strands are synthesized separately and thenhybridized together using standard techniques. This double-strandedoligonucleotide is referred to as the cassette. This cassette isdesigned to have 3′ and 5′ ends that are compatible with the ends of thelinearized plasmid, such that it can be directly ligated to the plasmid.This plasmid now contains the mutated TIE ligand DNA sequence.

[0075] Additionally, the so-called phagemid display method may be usefulin making amino acid sequence variants of native or variant TIE ligands.This method involves (a) constructing a replicable expression vectorcomprising a first gene encoding an receptor to be mutated, a secondgene encoding at least a portion of a natural or wild-type phage coatprotein wherein the first and second genes are heterologous, and atranscription regulatory element operably linked to the first and secondgenes, thereby forming a gene fusion encoding a fusion protein; (b)mutating the vector at one or more selected positions within the firstgene thereby forming a family of related plasmids; (c) transformingsuitable host cells with the plasmids; (d) infecting the transformedhost cells with a helper phage having a gene encoding the phage coatprotein; (e) culturing the transformed infected host cells underconditions suitable for forming recombinant phagemid particlescontaining at least a portion of the plasmid and capable of transformingthe host, the conditions adjusted so that no more than a minor amount ofphagemid particles display more than one copy of the fusion protein onthe surface of the particle; (f) contacting the phagemid particles witha suitable antigen so that at least a portion of the phagemid particlesbind to the antigen; and (g) separating the phagemid particles that bindfrom those that do not. Steps (d) through (g) can be repeated one ormore times. Preferably in this method the plasmid is under tight controlof the transcription regulatory element, and the culturing conditionsare adjusted so that the amount or number of phagemid particlesdisplaying more than one copy of the fusion protein on the surface ofthe particle is less than about 1%. Also, preferably, the amount ofphagemid particles displaying more than one copy of the fusion proteinis less than 10% of the amount of phagemid particles displaying a singlecopy of the fusion protein. Most preferably, the amount is less than20%. Typically in this method, the expression vector will furthercontain a secretory signal sequence fused to the DNA encoding eachsubunit of the polypeptide and the transcription regulatory element willbe a promoter system. Preferred promoter systems are selected from lacZ, λ_(PL), tac, T7 polymerase, tryptophan, and alkaline phosphatasepromoters and combinations thereof. Also, normally the method willemploy a helper phage selected from M13K07, M13R408, M13-VCS, and Phi X174. The preferred helper phage is M13K07, and the preferred coatprotein is the M13 Phage gene III coat protein. The preferred host is E.coli, and protease-deficient strains of E. coli.

[0076] Further details of the foregoing and similar mutagenesistechniques are found in general textbooks, such as, for example,Sambrook et al., Molecular Cloning: A laboratory Manual (New York: ColdSpring Harbor Laboratory Press, 1989), and Current Protocols inMolecular Biology, Ausubel et al., eds., Wiley-Interscience, 1991.

[0077] “Immunoadhesins” are chimeras which are traditionally constructedfrom a receptor sequence linked to an appropriate immunoglobulinconstant domain sequence (immunoadhesins). Such structures are wellknown in the art. Immunoadhesins reported in the literature includefusions of the T cell receptors [Gascoigne et al., Proc. Natl. Acad.Sci. USA 84, 2936-2940 (1987)]; CD4* [Capon et al., Nature 337, 525-531(1989); Traunecker et al., Nature 339, 68-70 (1989); Zettmeissl et al.,DNA Cell Biol. USA 9, 347-353 (1990); Byrn et al., Nature 344, 667-670(1990)]; L-selectin (homing receptor) [Watson et al., J. Cell. Biol.110, 2221-2229 (1990); Watson et al., Nature 349, 164-167 (1991)]; CD44*[Aruffo et al., Cell 61, 1303-1313 (1990)]; CD28* and B7* [Linsley etal., J. Exp. Med. 173, 721-730 (1991)]; CTLA-4* [Lisley et al., J. Exp.Med. 174, 561-569 (1991)]; CD22* [Stamenkovic et al., Cell 66. 1133-1144(1991)]; TNF receptor [Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88,10535-10539 (1991); Lesslauer et al., Eur. J. Immunol. 27, 2883-2886(1991); Peppel et al., J. Exp. Med. 174, 1483-1489 (1991)]; NP receptors[Bennett et al., J. Biol. Chem. 266, 23060-23067 (1991)]; IgE receptorα-chain* [Ridgway and Gorman, J. Cell. Biol. 115, abstr. 1448 (1991)];HGF receptor [Mark, M. R. et al., 1992, J. Biol. Chem. submitted], wherethe asterisk (*) indicates that the receptor is member of theimmunoglobulin superfamily.

[0078] Ligand-immunoglobulin chimeras are also known, and are disclosed,for example, in U.S. Pat. No. 5,304,640 (for L-selectin ligands); U.S.Pat. Nos. 5,316,921 and 5,328,837 (for HGF variants). These chimeras canbe made in a similar way to the construction of receptor-immunoglobulinchimeras.

[0079] Covalent modifications of the TIE ligands of the presentinvention are included within the scope herein. Such modifications aretraditionally introduced by reacting targeted amino acid residues of theTIE ligand with an organic derivatizing agent that is capable ofreacting with selected sides or terminal residues, or by harnessingmechanisms of post-translational modifications that function in selectedrecombinant host cells. The resultant covalent derivatives are useful inprograms directed at identifying residues important for biologicalactivity, for immunoassays, or for the preparation of anti-TIE ligandantibodies for immunoaffinity purification of the recombinant. Forexample, complete inactivation of the biological activity of the proteinafter reaction with ninhydrin would suggest that at least one arginyl orlysyl residue is critical for its activity, whereafter the individualresidues which were modified under the conditions selected areidentified by isolation of a peptide fragment containing the modifiedamino acid residue. Such modifications are within the ordinary skill inthe art and are performed without undue experimentation.

[0080] Cysteinyl residues most commonly are reacted with α-haloacetates(and corresponding amines), such as chloroacetic acid orchloroacetamide, to give carboxymethyl or carboxyamidomethylderivatives. Cysteinyl residues also are derivatized by reaction withbromotrifluoroacetone, α-bromo-β-(5-imidozoyl)propionic acid,chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide,methyl 2-pyridyl disulfide, p-chloromercuribenzoate,2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.

[0081] Histidyl residues are derivatized by reaction withdiethylpyrocarbonate at pH 5.5-7.0 because this agent is relativelyspecific for the histidyl side chain. Para-bromophenacyl bromide also isuseful; the reaction is preferably performed in 0.1M sodium cacodylateat pH 6.0.

[0082] Lysinyl and amino terminal residues are reacted with succinic orother carboxylic acid anhydrides. Derivatization with these agents hasthe effect of reversing the charge of the lysinyl residues. Othersuitable reagents for derivatizing a-amino-containing residues includeimidoesters such as methyl picolinimidate; pyridoxal phosphate;pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid;O-methylisourea; 2,4-pentanedione; and transaminase-catalyzed reactionwith glyoxylate.

[0083] Arginyl residues are modified by reaction with one or severalconventional reagents, among them phenylglyoxal, 2,3-butanedione,1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine residuesrequires that the reaction be performed in alkaline conditions becauseof the high pK_(a) of the guanidine functional group. Furthermore, thesereagents may react with the groups of lysine as well as the arginineepsilon-amino group.

[0084] The specific modification of tyrosyl residues may be made, withparticular interest in introducing spectral labels into tyrosyl residuesby reaction with aromatic diazonium compounds or tetranitromethane. Mostcommonly, N-acetylimidizole and tetranitromethane are used to formO-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosylresidues are iodinated using ¹²⁵I or ¹³¹I to prepare labeled proteinsfor use in radioimmunoassay.

[0085] Carboxyl side groups (aspartyl or glutamyl) are selectivelymodified by reaction with carbodiimides (R′—N═C═N—R′) such as1-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide or1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore,aspartyl and glutamyl residues are converted to asparaginyl andglutaminyl residues by reaction with ammonium ions.

[0086] Glutaminyl and asparaginyl residues are frequently deamidated tothe corresponding glutamyl and aspartyl residues. Alternatively, theseresidues are deamidated under mildly acidic conditions. Either form ofthese residues falls within the scope of this invention.

[0087] Other modifications include hydroxylation of proline and lysine,phosphorylation of hydroxyl groups of seryl, threonyl or tyrosylresidues, methylation of the α-amino groups of lysine, arginine, andhistidine side chains (T. E. Creighton, Proteins: Structure andMolecular Properties, W. H. Freeman & Co., San Francisco, pp. 79-86[1983]), acetylation of the N-terminal amine, and amidation of anyC-terminal carboxyl group. The molecules may further be covalentlylinked to nonproteinaceous polymers, e.g. polyethylene glycol,polypropylene glycol or polyoxyalkylenes, in the manner set forth inU.S. Ser. No. 07/275,296 or U.S. Pat. Nos. 4,640,835; 4,496,689;4,301,144; 4,670,417; 4,791,192 or 4,179,337.

[0088] Derivatization with bifunctional agents is useful for preparingintramolecular aggregates of the TIE ligand with polypeptides as well asfor cross-linking the TIE ligand polypeptide to a water insolublesupport matrix or surface for use in assays or affinity purification. Inaddition, a study of interchain cross-links will provide directinformation on conformational structure. Commonly used cross-linkingagents include 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde,N-hydroxysuccinimide esters, homobifunctional imidoesters, andbifunctional maleimides. Derivatizing agents such asmethyl-3-[(p-azidophenyl)dithio]propioimidate yield photoactivatableintermediates which are capable of forming cross-links in the presenceof light. Alternatively, reactive water insoluble matrices such ascyanogen bromide activated carbohydrates and the systems reactivesubstrates described in U.S. Pat. Nos. 3,959,642; 3,969,287; 3,691,016;4,195,128; 4,247,642; 4,229,537; 4,055,635; and 4,330,440 are employedfor protein immobilization and cross-linking.

[0089] Certain post-translational modifications are the result of theaction of recombinant host cells on the expressed polypeptide.Glutaminyl and aspariginyl residues are frequently post-translationallydeamidated to the corresponding glutamyl and aspartyl residues.Alternatively, these residues are deamidated under mildly acidicconditions. Either form of these residues falls within the scope of thisinvention.

[0090] Other post-translational modifications include hydroxylation ofproline and lysine, phosphorylation of hydroxyl groups of seryl,threonyl or tyrosyl residues, methylation of the α-amino groups oflysine, arginine, and histidine side chains [T. E. Creighton, Proteins:Structure and Molecular Properties, W. H. Freeman & Co., San Francisco,pp. 79-86 (1983)].

[0091] Other derivatives comprise the novel peptides of this inventioncovalently bonded to a nonproteinaceous polymer. The nonproteinaceouspolymer ordinarily is a hydrophilic synthetic polymer, i.e. a polymernot otherwise found in nature. However, polymers which exist in natureand are produced by recombinant or in vitro methods are useful, as arepolymers which are isolated from nature. Hydrophilic polyvinyl polymersfall within the scope of this invention, e.g. polyvinylalcohol andpolyvinylpyrrolidone. Particularly useful are polyvinylalkylene etherssuch a polyethylene glycol, polypropylene glycol.

[0092] The TIE ligands may be linked to various nonproteinaceouspolymers, such as polyethylene glycol (PEG), polypropylene glycol orpolyoxyalkylenes, in the manner set forth in U.S. Pat. Nos. 4,640,835;4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. These variants,just as the immunoadhesins of the present invention are expected to havelonger half-lives than the corresponding native TIE ligands.

[0093] The TIE ligands may be entrapped in microcapsules prepared, forexample, by coacervation techniques or by interfacial polymerization, incolloidal drug delivery systems (e.g. liposomes, albumin microspheres,microemulsions, nano-particles and nanocapsules), or in macroemulsions.Such techniques are disclosed in Remington's Pharmaceutical Sciences,16th Edition, Osol, A., Ed. (1980).

[0094] The term “native TIE receptor” is used herein to refer to a TIEreceptor of any animal species, including, but not limited to, humans,other higher primates, e.g. monkeys, and rodents, e.g. rats and mice.The definition specifically includes the TIE-2 receptor, disclosed, forexample, in PCT Application Serial No. WO 95/13387 (published May 18,1995), and the endothelial cell receptor tyrosine kinase termed “TIE” inPCT Application Publication No. WO 93/14124 (published Jul. 22, 1993),and preferably is TIE-2.

[0095] B. Anti-Tie Ligand Antibodies

[0096] The present invention covers agonist and antagonist antibodies,specifically binding the TIE ligands. The antibodies may be monoclonalor polyclonal, and include, without limitation, mature antibodies,antibody fragments (e.g. Fab, F(ab′)₂, F_(v), etc.), single-chainantibodies and various chain combinations.

[0097] The term “antibody” is used in the broadest sense andspecifically covers single monoclonal antibodies (including agonist,antagonist, and neutralizing antibodies) specifically binding a TIEligand of the present invention and antibody compositions withpolyepitopic specificity.

[0098] The term “monoclonal antibody” as used herein refers to anantibody obtained from a population of substantially homogeneousantibodies, i.e., the individual antibodies comprising the populationare identical except for possible naturally-occurring mutations that maybe present in minor amounts. Monoclonal antibodies are highly specific,being directed against a single antigenic site. Furthermore, in contrastto conventional (polyclonal) antibody preparations which typicallyinclude different antibodies directed against different determinants(epitopes), each monoclonal antibody is directed against a singledeterminant on the antigen.

[0099] The monoclonal antibodies herein include hybrid and recombinantantibodies produced by splicing a variable (including hypervariable)domain of an anti-TIE ligand antibody with a constant domain (e.g.“humanized” antibodies), or a light chain with a heavy chain, or a chainfrom one species with a chain from another species, or fusions withheterologous proteins, regardless of species of origin or immunoglobulinclass or subclass designation, as well as antibody fragments (e.g., Fab,F(ab′)₂, and Fv), so long as they exhibit the desired biologicalactivity. See, e.g. U.S. Pat. No. 4,816,567 and Mage et al., inMonoclonal Antibody Production Techniques and Applications, pp.79-97(Marcel Dekker, Inc.: New York, 1987).

[0100] Thus, the modifier “monoclonal” indicates the character of theantibody as being obtained from a substantially homogeneous populationof antibodies, and is not to be construed as requiring production of theantibody by any particular method. For example, the monoclonalantibodies to be used in accordance with the present invention may bemade by the hybridoma method first described by Kohler and Milstein,Nature, 256:495 (1975), or may be made by recombinant DNA methods suchas described in U.S. Pat. No. 4,816,567. The “monoclonal antibodies” mayalso be isolated from phage libraries generated using the techniquesdescribed in McCafferty et al., Nature, 348:552-554 (1990), for example.

[0101] “Humanized” forms of non-human (e.g. murine) antibodies arespecific chimeric immunoglobulins, immunoglobulin chains, or fragmentsthereof (such as Fv, Fab, Fab′, F(ab′)₂ or other antigen-bindingsubsequences of antibodies) which contain minimal sequence derived fromnon-human immunoglobulin. For the most part, humanized antibodies arehuman immunoglobulins (recipient antibody) in which residues from acomplementary determining region (CDR) of the recipient are replaced byresidues from a CDR of a non-human species (donor antibody) such asmouse, rat, or rabbit having the desired specificity, affinity, andcapacity. In some instances, Fv framework region (FR) residues of thehuman immunoglobulin are replaced by corresponding non-human residues.Furthermore, the humanized antibody may comprise residues which arefound neither in the recipient antibody nor in the imported CDR orframework sequences. These modifications are made to further refine andoptimize antibody performance. In general, the humanized antibody willcomprise substantially all of at least one, and typically two, variabledomains, in which all or substantially all of the CDR regions correspondto those of a non-human immunoglobulin and all or substantially all ofthe FR regions are those of a human immunoglobulin consensus sequence.The humanized antibody optimally also will comprise at least a portionof an immunoglobulin constant region or domain (Fc), typically that of ahuman immunoglobulin.

[0102] Polyclonal antibodies to a TIE ligand of the present inventiongenerally are raised in animals by multiple subcutaneous (sc) orintraperitoneal (ip) injections of the TIE ligand and an adjuvant. Itmay be useful to conjugate the TIE ligand or a fragment containing thetarget amino acid sequence to a protein that is immunogenic in thespecies to be immunized, e.g. keyhole limpet hemocyanin, serum albumin,bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctionalor derivatizing agent, for example maleimidobenzoyl sulfosuccinimideester (conjugation through cysteine residues), N-hydroxysuccinimide(through lysine residues), glytaraldehyde, succinic anhydride, SOCl₂, orR¹N═C═NR, where R and R¹ are different alkyl groups.

[0103] Animals are immunized against the immunogenic conjugates orderivatives by combining 1 mg or 1 μg of conjugate (for rabbits or mice,respectively) with 3 volumes of Freud's complete adjuvant and injectingthe solution intradermally at multiple sites. One month later theanimals are boosted with ⅕ to {fraction (1/10)} the original amount ofconjugate in Freud's complete adjuvant by subcutaneous injection atmultiple sites. 7 to 14 days later the animals are bled and the serum isassayed for anti-TIE ligand antibody titer. Animals are boosted untilthe titer plateaus. Preferably, the animal boosted with the conjugate ofthe same TIE ligand, but conjugated to a different protein and/orthrough a different cross-linking reagent. Conjugates also can be madein recombinant cell culture as protein fusions. Also, aggregating agentssuch as alum are used to enhance the immune response.

[0104] Monoclonal antibodies are obtained from a population ofsubstantially homogeneous antibodies, i.e., the individual antibodiescomprising the population are identical except for possiblenaturally-occurring mutations that may be present in minor amounts.Thus, the modifier “monoclonal” indicates the character of the antibodyas not being a mixture of discrete antibodies.

[0105] For example, the anti-TIE ligand monoclonal antibodies of theinvention may be made using the hybridoma method first described byKohler & Milstein, Nature 256:495 (1975), or may be made by recombinantDNA methods [Cabilly, et al., U.S. Pat. No. 4,816,567].

[0106] In the hybridoma method, a mouse or other appropriate hostanimal, such as hamster is immunized as hereinabove described to elicitlymphocytes that produce or are capable of producing antibodies thatwill specifically bind to the protein used for immunization.Alternatively, lymphocytes may be immunized in vitro. Lymphocytes thenare fused with myeloma cells using a suitable fusing agent, such aspolyethylene glycol, to form a hybridoma cell [Goding, MonoclonalAntibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)].

[0107] The hybridoma cells thus prepared are seeded and grown in asuitable culture medium that preferably contains one or more substancesthat inhibit the growth or survival of the unfused, parental myelomacells. For example, if the parental myeloma cells lack the enzymehypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), theculture medium for the hybridomas typically will include hypoxanthine,aminopterin, and thymidine (HAT medium), which substances prevent thegrowth of HGPRT-deficient cells.

[0108] Preferred myeloma cells are those that fuse efficiently, supportstable high level expression of antibody by the selectedantibody-producing cells, and are sensitive to a medium such as HATmedium. Among these, preferred myeloma cell lines are murine myelomalines, such as those derived from MOPC-21 and MPC-11 mouse tumorsavailable from the Salk Institute Cell Distribution Center, San Diego,Calif. USA, and SP-2 cells available from the American Type CultureCollection, Rockville, Md. USA. Human myeloma and mouse-humanheteromyeloma cell lines also have been described for the production ofhuman monoclonal antibodies [Kozbor, J. Immunol. 133:3001 (1984);Brodeur, et al., Monoclonal Antibody Production Techniques andApplications, pp.51-63 (Marcel Dekker, Inc., New York, 1987)].

[0109] Culture medium in which hybridoma cells are growing is assayedfor production of monoclonal antibodies directed against the TIE ligand.Preferably, the binding specificity of monoclonal antibodies produced byhybridoma cells is determined by immunoprecipitation or by an in vitrobinding assay, such as radioimmunoassay (RIA) or enzyme-linkedimmunoabsorbent assay (ELISA).

[0110] The binding affinity of the monoclonal antibody can, for example,be determined by the Scatchard analysis of Munson & Pollard, Anal.Biochem. 107:220 (1980).

[0111] After hybridoma cells are identified that produce antibodies ofthe desired specificity, affinity, and/or activity, the clones may besubcloned by limiting dilution procedures and grown by standard methods.Goding, Monoclonal Antibodies: Principles and Practice, pp.59-104(Academic Press, 1986). Suitable culture media for this purpose include,for example, Dulbecco's Modified Eagle's Medium or RPMI-1640 medium. Inaddition, the hybridoma cells may be grown in vivo as ascites tumors inan animal.

[0112] The monoclonal antibodies secreted by the subclones are suitablyseparated from the culture medium, ascites fluid, or serum byconventional immunoglobulin purification procedures such as, forexample, protein A-Sepharose, hydroxylapatite chromatography, gelelectrophoresis, dialysis, or affinity chromatography.

[0113] DNA encoding the monoclonal antibodies of the invention isreadily isolated and sequenced using conventional procedures (e.g., byusing oligonucleotide probes that are capable of binding specifically togenes encoding the heavy and light chains of murine antibodies). Thehybridoma cells of the invention serve as a preferred source of suchDNA. Once isolated, the DNA may be placed into expression vectors, whichare then transfected into host cells such as simian COS cells, Chinesehamster ovary (CHO) cells, or myeloma cells that do not otherwiseproduce immunoglobulin protein, to obtain the synthesis of monoclonalantibodies in the recombinant host cells. The DNA also may be modified,for example, by substituting the coding sequence for human heavy andlight chain constant domains in place of the homologous murinesequences, Morrison, et al., Proc. Nat. Acad. Sci. 81, 6851 (1984), orby covalently joining to the immunoglobulin coding sequence all or partof the coding sequence for a non-immunoglobulin polypeptide. In thatmanner, “chimeric” or “hybrid” antibodies are prepared that have thebinding specificity of an anti-TIE ligand monoclonal antibody herein.

[0114] Typically such non-immunoglobulin polypeptides are substitutedfor the constant domains of an antibody of the invention, or they aresubstituted for the variable domains of one antigen-combining site of anantibody of the invention to create a chimeric bivalent antibodycomprising one antigen-combining site having specificity for a TIEligand of the present invention and another antigen-combining sitehaving specificity for a different antigen.

[0115] Chimeric or hybrid antibodies also may be prepared in vitro usingknown methods in synthetic protein chemistry, including those involvingcrosslinking agents. For example, immunotoxins may be constructed usinga disulfide exchange reaction or by forming a thioether bond. Examplesof suitable reagents for this purpose include iminothiolate andmethyl-4-mercaptobutyrimidate.

[0116] For diagnostic applications, the antibodies of the inventiontypically will be labeled with a detectable moiety. The detectablemoiety can be any one which is capable of producing, either directly orindirectly, a detectable signal. For example, the detectable moiety maybe a radioisotope, such as ³H, ¹⁴C, ³²P, ³⁵S, or ¹²⁵I, a fluorescent orchemiluminescent compound, such as fluorescein isothiocyanate,rhodamine, or luciferin; biotin; radioactive isotopic labels, such as,e.g., ¹²⁵I, ³²P, ¹⁴C, or ³H, or an enzyme, such as alkaline phosphatase,beta-galactosidase or horseradish peroxidase.

[0117] Any method known in the art for separately conjugating theantibody to the detectable moiety may be employed, including thosemethods described by Hunter, et al., Nature 144:945 (1962); David, etal., Biochemistry 13:1014 (1974); Pain, et al., J. Immunol. Meth. 40:219(1981); and Nygren, J. Histochem. and Cytochem. 30:407 (1982).

[0118] The antibodies of the present invention may be employed in anyknown assay method, such as competitive binding assays, direct andindirect sandwich assays, and immunoprecipitation assays. Zola,Monoclonal Antibodies: A Manual of Techniques, pp.147-158 (CRC Press,Inc., 1987).

[0119] Competitive binding assays rely on the ability of a labeledstandard (which may be a TIE ligand or an immunologically reactiveportion thereof) to compete with the test sample analyte (TIE ligand)for binding with a limited amount of antibody. The amount of TIE ligandin the test sample is inversely proportional to the amount of standardthat becomes bound to the antibodies. To facilitate determining theamount of standard that becomes bound, the antibodies generally areinsolubilized before or after the competition, so that the standard andanalyte that are bound to the antibodies may conveniently be separatedfrom the standard and analyte which remain unbound.

[0120] Sandwich assays involve the use of two antibodies, each capableof binding to a different immunogenic portion, or epitope, of theprotein to be detected. In a sandwich assay, the test sample analyte isbound by a first antibody which is immobilized on a solid support, andthereafter a second antibody binds to the analyte, thus forming aninsoluble three part complex. David & Greene, U.S. Pat. No. 4,376,110.The second antibody may itself be labeled with a detectable moiety(direct sandwich assays) or may be measured using an anti-immunoglobulinantibody that is labeled with a detectable moiety (indirect sandwichassay). For example, one type of sandwich assay is an ELISA assay, inwhich case the detectable moiety is an enzyme.

[0121] Methods for humanizing non-human antibodies are well known in theart. Generally, a humanized antibody has one or more amino acid residuesintroduced into it from a source which is non-human. These non-humanamino acid residues are often referred to as “import” residues, whichare typically taken from an “import” variable domain. Humanization canbe-essentially performed following the method of Winter and co-workers[Jones et al., Nature 321, 522-525 (1986); Riechmann et al., Nature 332,323-327 (1988); Verhoeyen et al., Science 239, 1534-1536 (1988)], bysubstituting rodent CDRs or CDR sequences for the correspondingsequences of a human antibody. Accordingly, such “humanized” antibodiesare chimeric antibodies (Cabilly, supra), wherein substantially lessthan an intact human variable domain has been substituted by thecorresponding sequence from a non-human species. In practice, humanizedantibodies are typically human antibodies in which some CDR residues andpossibly some FR residues are substituted by residues from analogoussites in rodent antibodies.

[0122] It is important that antibodies be humanized with retention ofhigh affinity for the antigen and other favorable biological properties.To achieve this goal, according to a preferred method, humanizedantibodies are prepared by a process of analysis of the parentalsequences and various conceptual humanized products using threedimensional models of the parental and humanized sequences. Threedimensional immunoglobulin models are commonly available and arefamiliar to those skilled in the art. Computer programs are availablewhich illustrate and display probable three-dimensional conformationalstructures of selected candidate immunoglobulin sequences. Inspection ofthese displays permits analysis of the likely role of the residues inthe functioning of the candidate immunoglobulin sequence, i.e. theanalysis of residues that influence the ability of the candidateimmunoglobulin to bind its antigen. In this way, FR residues can beselected and combined from the consensus and import sequence so that thedesired antibody characteristic, such as increased affinity for thetarget antigen(s), is achieved. In general, the CDR residues aredirectly and most substantially involved in influencing antigen binding.For further details see U.S. application Ser. No. 07/934,373 filed Aug.21, 1992, which is a continuation-in-part of application Ser. No.07/715,272 filed Jun. 14, 1991.

[0123] Alternatively, it is now possible to produce transgenic animals(e.g. mice) that are capable, upon immunization, of producing a fullrepertoire of human antibodies in the absence of endogenousimmunoglobulin production. For example, it has been described that thehomozygous deletion of the antibody heavy chain joining region (J_(H))gene in chimeric and germ-line mutant mice results in completeinhibition of endogenous antibody production. Transfer of the humangerm-line immunoglobulin gene array in such germ-line mutant mice willresult in the production of human antibodies upon antigen challenge.See, e.g. Jakobovits et al., Proc. Natl. Acad. Sci. USA 90, 2551-255(1993); Jakobovits et al., Nature 362, 255-258 (1993).

[0124] Bispecific antibodies are monoclonal, preferably human orhumanized, antibodies that have binding specificities for at least twodifferent antigens. In the present case, one of the bindingspecificities is for a particular TIE ligand, the other one is for anyother antigen, and preferably for another ligand. For example,bispecific antibodies specifically binding two different TIE ligands arewithin the scope of the present invention.

[0125] Methods for making bispecific antibodies are known in the art.

[0126] Traditionally, the recombinant production of bispecificantibodies is based on the coexpression of two immunoglobulin heavychain-light chain pairs, where the two heavy chains have differentspecificities (Millstein and Cuello, Nature 305, 537-539 (1983)).Because of the random assortment of immunoglobulin heavy and lightchains, these hybridomas (quadromas) produce a potential mixture of 10different antibody molecules, of which only one has the correctbispecific structure. The purification of the correct molecule, which isusually done by affinity chromatography steps, is rather cumbersome, andthe product yields are low. Similar procedures are disclosed in PCTapplication publication No. WO 93/08829 (published May 13, 1993), and inTraunecker et al., EMBO 10, 3655-3659 (1991).

[0127] According to a different and more preferred approach, antibodyvariable domains with the desired binding specificities(antibody-antigen combining sites) are fused to immunoglobulin constantdomain sequences. The fusion preferably is with an immunoglobulin heavychain constant domain, comprising at least part of the hinge, and secondand third constant regions of an immunoglobulin heavy chain (CH2 andCH3). It is preferred to have the first heavy chain constant region(CH1) containing the site necessary for light chain binding, present inat least one of the fusions. DNAs encoding the immunoglobulin heavychain fusions and, if desired, the immunoglobulin light chain, areinserted into separate expression vectors, and are cotransfected into asuitable host organism. This provides for great flexibility in adjustingthe mutual proportions of the three polypeptide fragments in embodimentswhen unequal ratios of the three polypeptide chains used in theconstruction provide the optimum yields. It is, however, possible toinsert the coding sequences for two or all three polypeptide chains inone expression vector when the expression of at least two polypeptidechains in equal ratios results in high yields or when the ratios are ofno particular significance. In a preferred embodiment of this approach,the bispecific antibodies are composed of a hybrid immunoglobulin heavychain with a first binding specificity in one arm, and a hybridimmunoglobulin heavy chain-light chain pair (providing a second bindingspecificity) in the other arm. It was found that this asymmetricstructure facilitates the separation of the desired bispecific compoundfrom unwanted immunoglobulin chain combinations, as the presence of animmunoglobulin light chain in only one half of the bispecific moleculeprovides for a facile way of separation. This approach is disclosed incopending application Ser. No. 07/931,811 filed Aug. 17, 1992.

[0128] For further details of generating bispecific antibodies see, forexample, Suresh et al., Methods in Enzymology 121, 210 (1986).

[0129] Heteroconjugate antibodies are also within the scope of thepresent invention. Heteroconjugate antibodies are composed of twocovalently joined antibodies. Such antibodies have, for example, beenproposed to target immune system cells to unwanted cells (U.S. Pat. No.4,676,980), and for treatment of HIV infection (PCT applicationpublication Nos. WO 91/00360 and WO 92/200373; EP 03089).Heteroconjugate antibodies may be made using any convenient crosslinkingmethods. Suitable cross-linking agents are well known in the art, andare disclosed in U.S. Pat. No. 4,676,980, along with a number ofcross-linking techniques.

[0130] The term “agonist” is used to refer to peptide and non-peptideanalogs of the native TIE ligands of the present invention and toantibodies specifically binding such native TIE ligands, provided thatthey have the ability to signal through a native TIE receptor (e.g.TIE-2). In other words, the term “agonist” is defined in the context ofthe biological role of the TIE receptor, and not in relation to thebiological role of a native TIE ligand, which, as noted before, may bean agonist or antagonist of the TIE receptor biological function.Preferred agonists are promoters of vascularization.

[0131] The term “antagonist” is used to refer to peptide and non-peptideanalogs of the native TIE ligands of the present invention and toantibodies specifically binding such native TIE ligands, provided thatthey have the ability to inhibit the biological function of a native TIEreceptor (e.g. TIE-2). Again, the term “antagonist” is defined in thecontext of the biological role of the TIE receptor, and not in relationto the biological activity of a native TIE ligand, which may be eitheran agonist or an antagonist of the TIE receptor biological function.Preferred antagonists are inhibitors of vasculogenesis.

[0132] C. Cloning and Expression of the Tie Ligands

[0133] In the context of the present invention the expressions “cell”,“cell line”, and “cell culture” are used interchangeably, and all suchdesignations include progeny. It is also understood that all progeny maynot be precisely identical in DNA content, due to deliberate orinadvertent mutations. Mutant progeny that have the same function orbiological property, as screened for in the originally transformed cell,are included.

[0134] The terms “replicable expression vector” and “expression vector”refer to a piece of DNA, usually double-stranded, which may haveinserted into it a piece of foreign DNA. Foreign DNA is defined asheterologous DNA, which is DNA not naturally found in the host cell. Thevector is used to transport the foreign or heterologous DNA into asuitable host cell. Once in the host cell, the vector can replicateindependently of the host chromosomal DNA, and several copies of thevector and its inserted (foreign) DNA may be generated. In addition, thevector contains the necessary elements that permit translating theforeign DNA into a polypeptide. Many molecules of the polypeptideencoded by the foreign DNA can thus be rapidly synthesized.

[0135] Expression and cloning vectors are well known in the art andcontain a nucleic acid sequence that enables the vector to replicate inone or more selected host cells. The selection of the appropriate vectorwill depend on 1) whether it is to be used for DNA amplification or forDNA expression, 2) the size of the DNA to be inserted into the vector,and 3) the host cell to be transformed with the vector. Each vectorcontains various components depending on its function (amplification ofDNA of expression of DNA) and the host cell for which it is compatible.The vector components generally include, but are not limited to, one ormore of the following: a signal sequence, an origin of replication, oneor more marker genes, an enhancer element, a promoter, and atranscription termination sequence.

[0136] (i) Signal Sequence Component

[0137] In general, the signal sequence may be a component of the vector,or it may be a part of the TIE ligand molecule that is inserted into thevector. If the signal sequence is heterologous, it should be selectedsuch that it is recognized and processed (i.e. cleaved by a signalpeptidase) by the host cell.

[0138] Heterologous signal sequences suitable for prokaryotic host cellsare preferably prokaryotic signal sequences, such as the α-amylase,ompA, ompC, ompE, ompF, alkaline phosphatase, penicillinase, lpp, orheat-stable enterotoxin II leaders. For yeast secretion the yeastinvertase, amylase, alpha factor, or acid phosphatase leaders may, forexample, be used. In mammalian cell expression mammalian signalsequences are most suitable. The listed signal sequences are forillustration only, and do not limit the scope of the present inventionin any way.

[0139] (ii) Origin of Replication Component

[0140] Both expression and cloning vectors contain a nucleic acidsequence that enabled the vector to replicate in one or more selectedhost cells. Generally, in cloning vectors this sequence is one thatenables the vector to replicate independently of the host chromosomes,and includes origins of replication or autonomously replicatingsequences. Such sequence are well known for a variety of bacteria, yeastand viruses. The origin of replication from the well-known plasmidpBR322 is suitable for most gram negative bacteria, the 2μ plasmidorigin for yeast and various viral origins (SV40, polyoma, adenovirus,VSV or BPV) are useful for cloning vectors in mammalian cells. Originsof replication are not needed for mammalian expression vectors (the SV40origin may typically be used only because it contains the earlypromoter). Most expression vectors are “shuttle” vectors, i.e. they arecapable of replication in at least one class of organisms but can betransfected into another organism for expression. For example, a vectoris cloned in E. coli and then the same vector is transfected into yeastor mammalian cells for expression even though it is not capable ofreplicating independently of the host cell chromosome.

[0141] DNA is also cloned by insertion into the host genome. This isreadily accomplished using Bacillus species as hosts, for example, byincluding in the vector a DNA sequence that is complementary to asequence found in Bacillus genomic DNA. Transfection of Bacillus withthis vector results in homologous recombination with the genome andinsertion of the DNA encoding the desired heterologous polypeptide.However, the recovery of genomic DNA is more complex than that of anexogenously replicated vector because restriction enzyme digestion isrequired to excise the encoded polypeptide molecule.

[0142] (iii) Selection Gene Component

[0143] Expression and cloning vectors should contain a selection gene,also termed a selectable marker. This is a gene that encodes a proteinnecessary for the survival or growth of a host cell transformed with thevector. The presence of this gene ensures that any host cell whichdeletes the vector will not obtain an advantage in growth orreproduction over transformed hosts. Typical selection genes encodeproteins that (a) confer resistance to antibiotics or other toxins, e.g.ampicillin, neomycin, methotrexate or tetracycline, (b) complementauxotrophic deficiencies, or (c) supply critical nutrients not availablefrom complex media, e.g. the gene encoding D-alanine racemase forbacilli.

[0144] One example of a selection scheme utilizes a drug to arrestgrowth of a host cell. Those cells that are successfully transformedwith a heterologous gene express a protein conferring drug resistanceand thus survive the selection regimen. Examples of such dominantselection use the drugs neomycin [Southern et al., J. Molec. Appl.Genet. 1, 327 (1982)], mycophenolic acid [Mulligan et al., Science 209,1422 (1980)], or hygromycin [Sudgen et al., Mol. Cel. Biol. 5, 410-413(1985)]. The three examples given above employ bacterial genes undereukaryotic control to convey resistance to the appropriate drug G418 orneomycin (geneticin), xgpt (mycophenolic acid), or hygromycin,respectively.

[0145] Other examples of suitable selectable markers for mammalian cellsare dihydrofolate reductase (DHFR) or thymidine kinase. Such markersenable the identification of cells which were competent to take up thedesired nucleic acid. The mammalian cell transformants are placed underselection pressure which only the transformants are uniquely adapted tosurvive by virtue of having taken up the marker. Selection pressure isimposed by culturing the transformants under conditions in which theconcentration of selection agent in the medium is successively changed,thereby leading to amplification of both the selection gene and the DNAthat encodes the desired polypeptide. Amplification is the process bywhich genes in greater demand for the production of a protein criticalfor growth are reiterated in tandem within the chromosomes of successivegenerations of recombinant cells. Increased quantities of the desiredpolypeptide are synthesized from the amplified DNA. For example, cellstransformed with the DHFR selection gene are first identified byculturing all of the transformants in a culture medium which lackshypoxanthine, glycine, and thymidine. An appropriate host cell in thiscase is the Chinese hamster ovary (CHO) cell line deficient in DHFRactivity, prepared and propagated as described by Urlaub and Chasin,Proc. Nat'l. Acad. Sci. USA 77, 4216 (1980). A particularly useful DHFRis a mutant DHFR that is highly resistant to MTX (EP 117,060). Thisselection agent can be used with any otherwise suitable host, e.g. ATCCNo. CCL61 CHO-K1, notwithstanding the presence of endogenous DHFR. TheDNA encoding DHFR and the desired polypeptide, respectively, then isamplified by exposure to an agent (methotrexate, or MTX) thatinactivates the DHFR. One ensures that the cell requires more DHFR (andconsequently amplifies all exogenous DNA) by selecting only for cellsthat can grow in successive rounds of ever-greater MTX concentration.Alternatively, hosts co-transformed with genes encoding the desiredpolypeptide, wild-type DHFR, and another selectable marker such as theneo gene can be identified using a selection agent for the selectablemarker such as G418 and then selected and amplified using methotrexatein a wild-type host that contains endogenous DHFR. (See also U.S. Pat.No. 4,965,199).

[0146] A suitable selection gene for use in yeast is the trp 1 genepresent in the yeast plasmid YRp7 (Stinchcomb et al, 1979, Nature282:39; Kingsman et al., 1979, Gene 7:141; or Tschemper et al., 1980,Gene 10: 157). The trp 1 gene provides a selection marker for a mutantstrain of yeast lacking the ability to grow in tryptophan, for example,ATCC No. 44076 or PEP4-1 (Jones, 1977, Genetics 85:12). The presence ofthe trp 1 lesion in the yeast host cell genome then provides aneffective environment for detecting transformation by growth in theabsence of tryptophan. Similarly, Leu2 deficient yeast strains (ATCC20,622 or 38,626) are complemented by known plasmids bearing the Leu2gene.

[0147] (iv) Promoter Component

[0148] Expression vectors, unlike cloning vectors, should contain apromoter which is recognized by the host organism and is operably linkedto the nucleic acid encoding the desired polypeptide. Promoters areuntranslated sequences located upstream from the start codon of astructural gene (generally within about 100 to 1000 bp) that control thetranscription and translation of nucleic acid under their control. Theytypically fall into two classes, inducible and constitutive. Induciblepromoters are promoters that initiate increased levels of transcriptionfrom DNA under their control in response to some change in cultureconditions, e.g. the presence or absence of a nutrient or a change intemperature. At this time a large number of promoters recognized by avariety of potential host cells are well known. These promoters areoperably linked to DNA encoding the desired polypeptide by removing themfrom their gene of origin by restriction enzyme digestion, followed byinsertion 5′ to the start codon for the polypeptide to be expressed.This is not to say that the genomic promoter for a TIE ligand is notusable. However, heterologous promoters generally will result in greatertranscription and higher yields of expressed TIE ligands as compared tothe native TIE ligand promoters.

[0149] Promoters suitable for use with prokaryotic hosts include theβ-lactamase and lactose promoter systems (Chang et al., Nature 275:615(1978); and Goeddel et al., Nature 281:544 (1979)), alkalinephosphatase, a tryptophan (trp) promoter system (Goeddel, Nucleic AcidsRes. 8:4057 (1980) and EPO Appln. Publ. No. 36,776) and hybrid promoterssuch as the tac promoter (H. de Boer et al., Proc. Nat'l. Acad. Sci. USA80:21-25 (1983)). However, other known bacterial promoters are suitable.Their nucleotide sequences have been published, thereby enabling askilled worker operably to ligate them to DNA encoding a TIE ligand(Siebenlist et al., Cell 20:269 (1980)) using linkers or adaptors tosupply any required restriction sites. Promoters for use in bacterialsystems also will contain a Shine-Dalgarno (S.D.) sequence operablylinked-to the DNA encoding a TIE ligand.

[0150] Suitable promoting sequences for use with yeast hosts include thepromoters for 3-phosphoglycerate kinase (Hitzeman et al. J. Biol. Chem.255:2073 (1980)) or other glycolytic enzymes (Hess et al., J. Adv.Enzyme Reg. 7:149 (1978); and Holland, Biochemistry 17:4900 (1978)),such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase,pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphateisomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphateisomerase, phosphoglucose isomerase, and glucokinase.

[0151] Other yeast promoters, which are inducible promoters having theadditional advantage of transcription controlled by growth conditions,are the promoter regions for alcohol dehydrogenase 2, isocytochrome C,acid phosphatase, degradative enzymes associated with nitrogenmetabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase,and enzymes responsible for maltose and galactose utilization. Suitablevectors and promoters for use in yeast expression are further describedin R. Hitzeman et al., EP 73,657A. Yeast enhancers also areadvantageously used with yeast promoters.

[0152] Promoter sequences are known for eukaryotes. Virtually alleukaryotic genes have an AT-rich region located approximately 25 to 30bases upstream from the site where transcription is initiated. Anothersequence found 70 to 80 bases upstream from the start of transcriptionof many genes is a CXCAAT region where X may be any nucleotide. At the3′ end of most eukaryotic genes is an AATAAA sequence that may be thesignal for addition of the poly A tail to the 3′ end of the codingsequence. All of these sequences are suitably inserted into mammalianexpression vectors.

[0153] TIE ligand transcription from vectors in mammalian host cells maybe controlled by promoters obtained from the genomes of viruses such aspolyoma virus, fowlpox virus (UK 2,211,504 published Jul. 5, 1989),adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcomavirus, cytomegalovirus, a retrovirus, hepatitis-B virus and mostpreferably Simian Virus 40 (SV40), from heterologous mammalianpromoters, e.g. the actin promoter or an immunoglobulin promoter, fromheat shock promoters, and from the promoter normally associated with theTIE ligand sequence, provided such promoters are compatible with thehost cell systems.

[0154] The early and late promoters of the SV40 virus are convenientlyobtained as an SV40 restriction fragment which also contains the SV40viral origin of replication [Fiers et al., Nature 273:113 (1978),Mulligan and Berg, Science 209, 1422-1427 (1980); Pavlakis et al., Proc.Natl. Acad. Sci. USA 78, 7398-7402 (1981)]. The immediate early promoterof the human cytomegalovirus is conveniently obtained as a HindIII Erestriction fragment [Greenaway et al., Gene 18, 355-360 (1982)]. Asystem for expressing DNA in mammalian hosts using the bovine papillomavirus as a vector is disclosed in U.S. Pat. No. 4,419,446. Amodification of this system is described in U.S. Pat. No. 4,601,978. Seealso, Gray et al., Nature 295, 503-508 (1982) on expressing cDNAencoding human immune interferon in monkey cells; Reyes et al., Nature297, 598-601 (1982) on expressing human β-interferon cDNA in mouse cellsunder the control of a thymidine kinasepromoter from herpes simplexvirus; Canaani and Berg, Proc. Natl. Acad. Sci. USA 79, 5166-5170 (1982)on expression of the human interferon β1 gene in cultured mouse andrabbit cells; and Gorman et al., Proc. Natl. Acad. Sci., USA 79,6777-6781 (1982) on expression of bacterial CAT sequences in CV-1 monkeykidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells,HeLa cells, and mouse HIN-3T3 cells using the Rous sarcoma virus longterminal repeat as a promoter.

[0155] (v) Enhancer Element Component

[0156] Transcription of a DNA encoding the TIE ligands of the presentinvention by higher eukaryotes is often increased by inserting anenhancer sequence into the vector. Enhancers are cis-acting elements ofDNA, usually about from 10 to 300 bp, that act on a promoter to increaseits transcription. Enhancers are relatively orientation and positionindependent having been found 5′ [Laimins et al., Proc. Natl. Acad. Sci.USA 78, 993 (1981)] and 3′ [Lasky et al., Mol Cel. Biol. 3, 1108 (1983)]to the transcription unit, within an intron [Banerji et al., Cell 33,729 (1983)] as well as within the coding sequence itself [Osborne etal., Mol. Cel. Biol. 4, 1293 (1984)]. Many enhancer sequences are nowknown from mammalian genes (globin, elastase, albumin, α-fetoprotein andinsulin). Typically, however, one will use an enhancer from a eukaryoticcell virus. Examples include the SV40 enhancer on the late side of thereplication origin (bp 100-270), the cytomegalovirus early promoterenhancer, the polyoma enhancer on the late side of the replicationorigin, and adenovirus enhancers. See also Yaniv, Nature 297, 17-18(1982) on enhancing elements for activation of eukaryotic promoters. Theenhancer may be spliced into the vector at a position 5′ or 3′ to theTIE ligand DNA, but is preferably located at a site 5′ from thepromoter.

[0157] (vi) Transcription Termination Component

[0158] Expression vectors used in eukaryotic host cells (yeast, fungi,insect, plant, animal, human, or nucleated cells from othermulticellular organisms) will also contain sequences necessary for thetermination of transcription and for stabilizing the mRNA. Suchsequences are commonly available from the 5′ and, occasionally 3′untranslated regions of eukaryotic or viral DNAs or cDNAs. These regionscontain nucleotide segments transcribed as polyadenylated fragments inthe untranslated portion of the mRNA encoding the TIE ligand. The 3′untranslated regions also include transcription termination sites.

[0159] Construction of suitable vectors containing one or more of theabove listed components, the desired coding and control sequences,employs standard ligation techniques. Isolated plasmids or DNA fragmentsare cleaved, tailored, and religated in the form desired to generate theplasmids required.

[0160] For analysis to confirm correct sequences in plasmidsconstructed, the ligation mixtures are used to transform E. coli K12strain 294 (ATCC 31,446) and successful transformants selected byampicillin or tetracycline resistance where appropriate. Plasmids fromthe transformants are prepared, analyzed by restriction endonucleasedigestion, and/or sequenced by the method of Messing et al., NucleicAcids Res. 9, 309 (1981) or by the method of Maxam et al., Methods inEnzymology 65, 499 (1980).

[0161] Particularly useful in the practice of this invention areexpression vectors that provide for the transient expression inmammalian cells of DNA encoding a TIE ligand. In general, transientexpression involves the use of an expression vector that is able toreplicate efficiently in a host cell, such that the host cellaccumulates many copies of the expression vector and, in turn,synthesizes high levels of a desired polypeptide encoded by theexpression vector. Transient systems, comprising a suitable expressionvector and a host cell, allow for the convenient positive identificationof polypeptides encoded by clones DNAs, as well as for the rapidscreening of such polypeptides for desired biological or physiologicalproperties. Thus, transient expression systems are particularly usefulin the invention for purposes of identifying analogs and variants of aTIE ligand.

[0162] Other methods, vectors, and host cells suitable for adaptation tothe synthesis of the TIE polypeptides in recombinant vertebrate cellculture are described in Getting et al., Nature 293, 620-625 (1981);Mantel et al., Nature 281, 40-46 (1979); Levinson et al.; EP 117,060 andEP 117,058. A particularly useful plasmid for mammalian cell cultureexpression of the TIE ligand polypeptides is pRK5 (EP 307,247), alongwith its derivatives, such as, pRK5D that has an sp6 transcriptioninitiation site followed by an SfiI restriction enzyme site precedingthe Xho/NotlI cDNA cloning sites, and pRK5B, a precursor of pRK54D thatdoes not contain the SfiI site; see, Holmes et al., Science 253,1278-1280 (1991).

[0163] (vii) Construction and Analysis of Vectors

[0164] Construction of suitable vectors containing one or more of theabove listed components employs standard ligation techniques. Isolatedplasmids or DNA fragments are cleaved, tailored, and religated in theform desired to generate the plasmids required.

[0165] For analysis to confirm correct sequences in plasmidsconstructed, the ligation mixtures are used to transform E. coli K12strain 294 (ATCC 31,446) and successful transformants selected byampicillin or tetracycline resistance where appropriate. Plasmids fromthe transformants are prepared, analyzed by restriction endonucleasedigestion, and/or sequences by the methods of Messing et al., NucleiAcids Res. 9, 309 (1981) or by the method of Maxam et al., Methods inEnzymology 65, 499 (1980).

[0166] (viii) Transient Expression Vectors

[0167] Particularly useful in the practice of this invention areexpression vectors that provide for the transient expression inmammalian cells of DNA encoding a TIE ligand. In general, transientexpression involves the use of an expression vector that is able toreplicate efficiently in a host cell, such that the host cellaccumulates many copies of the expression vector and, in turn,synthesizes high level of a desired polypeptide encoded by theexpression vector. Sambrook et al., supra, pp. 16.17-16.22. Transientexpression systems, comprising a suitable expression vector and a hostcell, allow for the convenient positive screening of such polypeptidesfor desired biological or physiological properties. Thus transientexpression systems are particularly useful in the invention for purposesof identifying analogs and variants of native TIE ligands with therequisite biological activity.

[0168] (ix) Suitable Exemplary Vertebrate Cell Vectors

[0169] Other methods, vectors, and host cells suitable for adaptation tothe synthesis of a TIE ligand (including functional derivatives ofnative proteins) in recombinant vertebrate cell culture are described inGething et al., Nature 293, 620-625 (1981); Mantei et al., Nature 281,40-46 (1979); Levinson et al., EP 117,060; and EP 117,058. Aparticularly useful plasmid for mammalian cell culture expression of aTIE ligand is pRK5 (EP 307,247) or pSVI6B (PCT Publication No. WO91/08291).

[0170] Suitable host cells for cloning or expressing the vectors hereinare the prokaryote, yeast or higher eukaryote cells described above.Suitable prokaryotes include gram negative or gram positive organisms,for example E. coli or bacilli. A preferred cloning host is E. coli 294(ATCC 31,446) although other gram negative or gram positive prokaryotessuch as E. coli B. E. coli X 1776 (ATCC 31,537), E. coli W3110 (ATCC27,325), Pseudomonas species, or Serratia Marcesans are suitable.

[0171] In addition to prokaryotes, eukaryotic microbes such asfilamentous fungi or yeast are suitable hosts for vectors herein.Saccharomyces cerevisiae, or common baker's yeast, is the most commonlyused among lower eukaryotic host microorganisms. However, a number ofother genera, species and strains are commonly available and usefulherein, such as S. pombe [Beach and Nurse, Nature 290, 140 (1981)],Kluyveromyces lactis [Louvencourt et al., J. Bacteriol. 737 (1983)];yarrowia (EP 402,226); Pichia pastoris (EP 183,070), Trichoderma reesia(EP 244,234), Neurospora crassa [Case et al., Proc. Natl. Acad. Sci. USA76, 5259-5263 (1979)]; and Aspergillus hosts such as A. nidulans[Ballance et al., Biochem. Biophys. Res. Commun. 112, 284-289 (1983);Tilburn et al., Gene 26, 205-221 (1983); Yelton et al., Proc. Natl.Acad. Sci. USA 81, 1470-1474 (1984)] and A. niger [Kelly and Hynes, EMBOJ. 4, 475-479 (1985)].

[0172] Suitable host cells may also derive from multicellular organisms.Such host cells are capable of complex processing and glycosylationactivities. In principle, any higher eukaryotic cell culture isworkable, whether from vertebrate or invertebrate culture, althoughcells from mammals such as humans are preferred. Examples ofinvertebrate cells include plants and insect cells. Numerous baculoviralstrains and variants and corresponding permissive insect host cells fromhosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti(mosquito), Aedes albopictus (mosquito), Drosophila melangaster(fruitfly), and Bombyx mori host cells have been identified. See, e.g.Luckow et al., Bio/Technology 6, 47-55 (1988); Miller et al., in GeneticEngineering, Setlow, J. K. et al., eds., Vol. 8 (Plenum Publishing,1986), pp. 277-279; and Maeda et al., Nature 315, 592-594 (1985). Avariety of such viral strains are publicly available, e.g. the L-1variant of Autographa californica NPV, and such viruses may be used asthe virus herein according to the present invention, particularly fortransfection of Spodoptera frugiperda cells.

[0173] Generally, plant cells are transfected by incubation with certainstrains of the bacterium Agrobacterium tumefaciens, which has beenpreviously manipulated to contain the TIE ligand DNA. During incubationof the plant cell culture with A. tumefaciens, the DNA encoding a TIEligand is transferred to the plant cell host such that it istransfected, and will, under appropriate conditions, express the TIEligand DNA. In addition, regulatory and signal sequences compatible withplant cells are available, such as the nopaline synthase promoter andpolyadenylation signal sequences. Depicker et al., J. Mol. Appl. Gen. 1,561 (1982). In addition, DNA segments isolated from the upstream regionof the T-DNA 780 gene are capable of activating or increasingtranscription levels of plant-expressible genes in recombinantDNA-containing plant tissue. See EP 321,196 published Jun. 21, 1989.

[0174] However, interest has been greatest in vertebrate cells, andpropagation of vertebrate cells in culture (tissue culture) is per sewell known. See Tissue Culture, Academic Press, Kruse and Patterson,editors (1973). Examples of useful mammalian host cell lines are monkeykidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); humanembryonic kidney cell line [293 or 293 cells subcloned for growth insuspension culture, Graham et al., J. Gen. Virol. 36, 59 (1977)]; babyhamster kidney cells 9BHK, ATCC CCL 10); Chinese hamster ovarycells/-DHFR [CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA 77, 4216(1980)]; mouse sertolli cells [TM4, Mather, Biol. Reprod. 23, 243-251(1980)]; monkey kidney cells (CV1 ATCC CCL 70); African green monkeykidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells(HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo ratliver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCCCCL75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT060562, ATCC CCL51); TRI cells [Mather et al., Annals N.Y. Acad. Sci.383, 44068 (1982)]; MRC 5 cells; FS4 cells; and a human hepatoma cellline (Hep G2). Preferred host cells are human embryonic kidney 293 andChinese hamster ovary cells.

[0175] Particularly preferred host cells for the purpose of the presentinvention are vertebrate cells producing the TIE ligands of the presentinvention.

[0176] Host cells are transfected and preferably transformed with theabove-described expression or cloning vectors and cultured inconventional nutrient media modified as is appropriate for inducingpromoters or selecting transformants containing amplified genes.

[0177] Prokaryotes cells used to produced the TIE ligands of thisinvention are cultured in suitable media as describe generally inSambrook et al., supra.

[0178] Mammalian cells can be cultured in a variety of media.Commercially available media such as Ham's F10 (Sigma), MinimalEssential Medium (MEM, Sigma), RPMI-1640 (Sigma), and Dulbecco'sModified Eagle's Medium (DMEM, Sigma) are suitable for culturing thehost cells. In addition, any of the media described in Ham and Wallace,Meth. Enzymol. 58, 44 (1979); Barnes and Sato, Anal. Biochem. 102, 255(1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; or 4,560,655; WO90/03430; WO 87/00195 or U.S. Pat. Re. No. 30,985 may be used as culturemedia for the host cells. Any of these media may be supplemented asnecessary with hormones and/or other growth factors (such as insulin,transferrin, or epidermal growth factor), salts (such as sodiumchloride, calcium, magnesium, and phosphate), buffers (such as HEPES),nucleosides (such as adenosine and thymidine), antibiotics (such asGentamycin™ drug) trace elements (defined as inorganic compounds usuallypresent at final concentrations in the micromolar range), and glucose oran equivalent energy source. Any other necessary supplements may also beincluded at appropriate concentrations that would be known to thoseskilled in the art. The culture conditions, such as temperature, pH andthe like, suitably are those previously used with the host cell selectedfor cloning or expression, as the case may be, and will be apparent tothe ordinary artisan.

[0179] The host cells referred to in this disclosure encompass cells inin vitro cell culture as well as cells that are within a host animal orplant.

[0180] It is further envisioned that the TIE ligands of this inventionmay be produced by homologous recombination, or with recombinantproduction methods utilizing control elements introduced into cellsalready containing DNA encoding the particular TIE ligand.

[0181] Gene amplification and/or expression may be measured in a sampledirectly, for example, by conventional Southern blotting, Northernblotting to quantitate the transcription of mRNA [Thomas, Proc. Natl.Acad. Sci. USA 77, 5201-5205 (1980)], dot blotting (DNA analysis), or insitu hybridization, using an appropriately labeled probe, based on thesequences provided herein. Various labels may be employed, most commonlyradioisotopes, particularly ³²P However, other techniques may also beemployed, such as using biotin-modified nucleotides for introductioninto a polynucleotide. The biotin then serves as a site for binding toavidin or antibodies, which may be labeled with a wide variety oflabels, such as radionuclides, fluorescers, enzymes, or the like.Alternatively, antibodies may be employed that can recognize specificduplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybridduplexes or DNA-protein duplexes. The antibodies in turn may be labeledand the assay may be carried out where the duplex is bound to thesurface, so that upon the formation of duplex on the surface, thepresence of antibody bound to the duplex can be detected.

[0182] Gene expression, alternatively, may be measured by immunologicalmethods, such as immunohistochernical staining of tissue sections andassay of cell culture or body fluids, to quantitate directly theexpression of gene product. With immunohistochemical stainingtechniques, a cell sample is prepared, typically by dehydration andfixation, followed by reaction with labeled antibodies specific for thegene product coupled, where the labels are usually visually detectable,such as enzymatic labels, fluorescent labels, luminescent labels, andthe like. A particularly sensitive staining technique suitable for usein the present invention is described by Hse et al., Am. J. Clin. Pharm.75, 734-738 (1980).

[0183] Antibodies useful for immunohistochemical staining and/or assayof sample fluids may be either monoclonal or polyclonal, and may beprepared in any animal. Conveniently, the antibodies may be preparedagainst a native TIE ligand polypeptide of the present invention, oragainst a synthetic peptide based on the DNA sequence provided herein asdescribed further hereinbelow.

[0184] The TIE ligand may be produced in host cells in the form ofinclusion bodies or secreted into the periplasmic space or the culturemedium, and is typically recovered from host cell lysates. Therecombinant ligands may be purified by any technique allowing for thesubsequent formation of a stable protein.

[0185] When the TIE ligand is expressed in a recombinant cell other thanone of human origin, it is completely free of proteins or polypeptidesof human origin. However, it is necessary to purify the TIE ligand fromrecombinant cell proteins or polypeptides to obtain preparations thatare substantially homogenous as to the ligand. As a first step, theculture medium or lysate is centrifuged to remove particulate celldebris. The membrane and soluble protein fractions are then separated.The TIE ligand may then be purified from the soluble protein fraction.The following procedures are exemplary of suitable purificationprocedures: fractionation on immunoaffinity or ion-exchange columns;ethanol precipitation; reverse phase HPLC; chromatography on silica oron a cation exchange resin such as DEAE; chromatofocusing; SDS-PAGE;ammonium sulfate precipitation; gel filtration using, for example,Sephadex G-75; and protein A Sepharose columns to remove contaminantssuch as IgG.

[0186] Functional derivatives of the TIE ligands in which residues havebeen deleted, inserted and/or substituted are recovered in the samefashion as the native ligands, taking into account of any substantialchanges in properties occasioned by the alteration. For example, fusionof the TIE ligand with another protein or polypeptide, e.g. a bacterialor viral antigen, facilitates purification; an immunoaffinity columncontaining antibody to the antigen can be used to absorb the fusion.Immunoaffinity columns such as a rabbit polyclonal anti-TIE ligandcolumn can be employed to absorb TIE ligand variants by binding to atleast one remaining immune epitope. A protease inhibitor, such as phenylmethyl sulfonyl fluoride (PMSF) also may be useful to inhibitproteolytic degradation during purification, and antibiotics may beincluded to prevent the growth of adventitious contaminants. The TIEligands of the present invention are conveniently purified by affinitychromatography, based upon their ability to bind to a TIE receptor, e.g.TIE-2.

[0187] One skilled in the art will appreciate that purification methodssuitable for native TIE ligands may require modification to account forchanges in the character of a native TIE ligand or its variants uponexpression in recombinant cell culture

[0188] D. Use of the Tie Ligands, Nucleic Acid Molecules and Antibodies

[0189] The TIE ligands of the present invention are useful in promotingthe survival and/or growth and/or differentiation of TIE receptor (e.g.TIE-2 receptor) expressing cells in cell culture.

[0190] The TIE ligands may be additionally used to identify cells whichexpress native TIE receptors, e.g. the TIE-2 receptor. To this end, adetectably labeled ligand is contacted with a target cell undercondition permitting its binding to the TIE receptor, and the binding ismonitored.

[0191] The TIE ligands herein may also be used to identify moleculesexhibiting a biological activity of a TIE ligand, for example, byexposing a cell expressing a TIE ligand herein to a test molecule, anddetecting the specific binding of the test molecule to a TIE (e.g.TIE-2) receptor, either by direct detection, or base upon secondarybiological effects. This approach is particularly suitable foridentifying new members of the TIE ligand family, or for screeningpeptide or non-peptide small molecule libraries.

[0192] The TIE ligands disclosed herein are also useful in screeningassays designed to identify agonists or antagonists of a native TIE(e.g. TIE-2) receptor that play an important role in bone development,maturation or growth, or in muscle growth or development and/or promoteor inhibit angiogenesis. For example, antagonists of the TIE-2 receptormay be identified based upon their ability to block the binding of a TIEligand of the present invention to a native TIE receptor, as measured,for example, by using BiAcore biosensor technology (BIAcore; PharmaciaBiosensor, Midscataway, N.J.); or by monitoring their ability to blockthe biological response caused by a biologically active TIE ligandherein. Biological responses that may be monitored include, for example,the phosphorylation of the TIE-2 receptor or downstream components ofthe TIE-2 signal transduction pathway, or survival, growth ordifferentiation of cells expressing the TIE-2 receptor. Cell-basedassays, utilizing cells that do not normally the TIE-2 receptor,engineered to express this receptor, or to coexpress the TIE-2 receptorand a TIE ligand of the present invention, are particularly convenientto use.

[0193] In a particular embodiment, small molecule agonists andantagonists of a native TIE receptor, e.g. the TIE-2 receptor, can beidentified, based upon their ability to interfere with the TIEligand/TIE receptor interaction. There are numerous ways for measuringthe specific binding of a test molecule to a TIE receptor, including,but not limited to detecting or measuring the amount of a test moleculebound to the surface of intact cells expressing the TIE receptor,cross-linked to the TIE receptor in cell lysates, or bound to the TIEreceptor in vitro.

[0194] Detectably labeled TIE ligands include, for example, TIE ligandscovalently or non-covalently linked to a radioactive substances, e.g.¹²⁵I, a fluorescent substance, a substance having enzymatic activity(preferably suitable for calorimetric detection), a substrate for anenzyme (preferably suitable for colorimetric detection), or a substancethat can be recognized by a(n) (detectably labeled) antibody molecule.

[0195] The assays of the present invention may be performed in amanner-similar to that described in PCT Publication WO 96/11269,published Apr. 18, 1996.

[0196] The TIE ligands of the present invention are also useful forpurifying TIE receptors, e.g. TIE-2 receptors, optionally used in theform of immunoadhesins, in which the TIE ligand or the TIE receptorbinding portion thereof is fused to an immunoglobulin heavy or lightchain constant region.

[0197] The nucleic acid molecules of the present invention are usefulfor detecting the expression of TIE ligands in cells or tissue sections.Cells or tissue sections may be contacted with a detectably labelednucleic acid molecule encoding a TIE ligand of the present inventionunder hybridizing conditions, and the presence of mRNA hybridized to thenucleic acid molecule determined, thereby detecting the expression ofthe TIE ligand.

[0198] Antibodies of the present invention may, for example, be used inimmunoassays to measure the amount of a TIE ligand in a biologicalsample. The biological sample is contacted with an antibody or antibodymixture specifically binding the a TIE ligand of the present invention,and the amount of the complex formed with a ligand present in the testsample is measured.

[0199] Antibodies to the TIE ligands herein may additionally be used forthe delivery of cytotoxic molecules, e.g. radioisotopes or toxins, ortherapeutic agents to cells expressing a corresponding TIE receptor. Thetherapeutic agents may, for example, be other TIE ligands, including theTIE-2 ligand, members of the vascular endothelial growth factor (VEGF)family, or known anti-tumor agents, and agents known to be associatedwith muscle growth or development, or bone development, maturation, orgrowth.

[0200] Anti-TIE ligand antibodies are also suitable as diagnosticagents, to detect disease states associated with the expression of a TIE(e.g. TIE-2) receptor. Thus, detectably labeled TIE ligands and antibodyagonists of a TIE receptor can be used for imaging the presence ofantiogenesis.

[0201] In addition, the new TIE ligands herein can be used to promoteneovascularization, and may be useful for inhibiting tumor growth.

[0202] Further potential therapeutic uses include the modulation ofmuscle and bone development, maturation, or growth.

[0203] For therapeutic use, the TIE ligands or anti-TIE ligandantibodies of the present invention are formulated as therapeuticcomposition comprising the active ingredient(s) in admixture with apharmacologically acceptable vehicle, suitable for systemic or topicalapplication. The pharmaceutical compositions of the present inventionare prepared for storage by mixing the active ingredient having thedesired degree of purity with optional physiologically acceptablecarriers, excipients or stabilizers (Remington's Pharmaceutical Sciences16th edition, Osol, A. Ed. (1980)), in the form of lyophilizedformulations or aqueous solutions. Acceptable carriers, excipients orstabilizers are nontoxic to recipients at the dosages and concentrationsemployed, and include buffers such as phosphate, citrate and otherorganic acids; antioxidants including ascorbic acid; low molecularweight (less than about 10 residues) polypeptides; proteins, such asserum albumin, gelatin or immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone, amino acids such as glycine, glutamine,asparagine, arginine or lysine; monosaccharides, disaccharides and othercarbohydrates including glucose, mannose, or dextrins; chelating agentssuch as EDTA; sugar alcohols such as mannitol or sorbitol; salt-formingcounterions such as sodium; and/or nonionic surfactants such as Tween,Pluronics or PEG.

[0204] The active ingredients may also be entrapped in microcapsulesprepared, for example, by coacervation techniques or by interfacialpolymerization, for example, hydroxymethylcellulose orgelatin-microcapsules and poly-(methylmethacylate) microcapsules,respectively), in colloidal drug delivery systems (for example,liposomes, albumin microspheres, microemulsions, nano-particles andnanocapsules) or in macroemulsions. Such techniques are disclosed inRemington's Pharmaceutical Sciences, supra.

[0205] The formulations to be used for in vivo administration must besterile. This is readily accomplished by filtration through sterilefiltration membranes, prior to or following lyophilization andreconstitution.

[0206] Therapeutic compositions herein generally are placed into acontainer having a sterile access port, for example, an intravenoussolution bag or vial having a stopper pierceable by a hypodermicinjection needle.

[0207] The route of administration is in accord with known methods, e.g.injection or infusion by intravenous, intraperitoneal, intracerebral,intramuscular, intraocular, intraarterial or intralesional routes,topical administration, or by sustained release systems.

[0208] Suitable examples of sustained release preparations includesemipermeable polymer matrices in the form of shaped articles, e.g.films, or microcapsules. Sustained release matrices include polyesters,hydrogels, polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymersof L-glutamic acid and gamma ethyl-L-glutamate (U. Sidman et al., 1983,“Biopolymers” 22 (1): 547-556), poly (2-hydroxyethyl-methacrylate) (R.Langer, et al., 1981, “J. Biomed. Mater. Res.” 15: 167-277 and R.Langer, 1982, Chem. Tech.” 12: 98-105), ethylene vinyl acetate (R.Langer et al., Id.) or poly-D-(−)-3-hydroxybutyric acid (EP 133,988A).Sustained release compositions also include liposomes. Liposomescontaining a molecule within the scope of the present invention areprepared by methods known per se: DE 3,218,121A; Epstein et al., 1985,“Proc. Natl. Acad. Sci. USA” 82: 3688-3692; Hwang et al., 1980, “Proc.Natl. Acad. Sci. USA” 77: 40304034; EP 52322A; EP 36676A; EP 88046A; EP143949A; EP 142641A; Japanese patent application 83-118008; U.S. Pat.Nos. 4,485,045 and 4,544,545; and EP 102,324A. Ordinarily the liposomesare of the small (about 200-800 Angstroms) unilamelar type in which thelipid content is greater than about 30 mol. % cholesterol, the selectedproportion being adjusted for the optimal NT-4 therapy.

[0209] An effective amount of a molecule of the present invention to beemployed therapeutically will depend, for example, upon the therapeuticobjectives, the route of administration, and the condition of thepatient. Accordingly, it will be necessary for the therapist to titerthe dosage and modify the route of administration as required to obtainthe optimal therapeutic effect. A typical daily dosage might range fromabout 1 μg/kg to up to 100 mg/kg or more, depending on the factorsmentioned above. Typically, the clinician will administer a molecule ofthe present invention until a dosage is reached that provides therequired biological effect. The progress of this therapy is easilymonitored by conventional assays.

[0210] Further details of the invention will be apparent from thefollowing non-limiting examples.

REFERENCE EXAMPLE 1

[0211] Identification of the FLS 139 Ligand

[0212] FLS 139 was identified in a cDNA library prepared from humanfetal liver mRNA obtained from Clontech Laboratories, Inc. Palo Alto,Calif. USA, catalog no. 64018-1, following the protocol described in“Instruction Manual: Superscript® Lambda System for cDNA Synthesis and λcloning,” cat. No. 19643-014, Life Technologies, Gaithersburg, Md., USAwhich is herein incorporated by reference. Unless otherwise noted, allreagents were also obtained from Life Technologies. The overallprocedure can be summarized into the following steps: (1) First strandsynthesis; (2) Second strand synthesis; (3) Adaptor addition; (4)Enzymatic digestion; (5) Gel isolation of cDNA; (6) Ligation intovector; and (7) Transformation.

[0213] First Strand Synthesis:

[0214] Not1 primer-adapter (Life Tech., 2 μl, 0.5 μg/μl) was added to asterile 1.5 ml microcentrifuge tube to which was added poly A+ mRNA (7μl, 5 μg). The reaction tube was heated to 70° C. for 5 minutes or timesufficient to denature the secondary structure of the mRNA. The reactionwas then chilled on ice and 5X First strand buffer (Life Tech., 4 μl),0.1 M DTT (2 μl) and 10 mM dNTP Mix (Life Tech., 1 μl) were added andthen heated to 37° C. for 2 minutes to equilibrate the temperature.Superscript II® reverse transcriptase (Life Tech., 5 μl) was then added,the reaction tube mixed well and incubated at 37° C. for 1 hour, andterminated by placement on ice. The final concentration of the reactantswas the following: 50 mM Tris-HCI (pH 8.3); 75 mM KCl; 3 mM MgCl₂; 10 mMDTT; 500 μM each dATP, dCTP, dGTP and dTTP; 50 μg/ml Not 1primer-adapter; 5 μg (250 μg/ml) mRNA; 50,000 U/ml Superscript II®reverse transcriptase.

[0215] Second Strand Synthesis:

[0216] While on ice, the following reagents were added to the reactiontube from the first strand synthesis, the reaction well mixed andallowed to react at 16° C. for 2 hours, taking care not to allow thetemperature to go above 16° C.: distilled water (93 μl); 5×Second strandbuffer (30 μl); dNTP mix (3 μl); 10 U/μl E. Coli DNA ligase (1 μl); 10U/μl E. Coli DNA polymerase I (4 μl); 2 U/μl E. Coli RNase H (1 μl). 10U T4 DNA Polymerase (2 μl) was added and the reaction continued toincubate at 16° C. for another 5 minutes. The-final concentration of thereaction was the following: 25 mM Tris-HCI (pH 7.5); 100 mM KCl; 5 MMMgCl₂; 10 mM (NH₄)₂SO₄; 0.15 mM β-NAD+; 250 μM each dATP, dCTP, dGTP,dTTP; 1.2 mM DTT; 65 U/ml DNA ligase; 250 U/ml DNA polymerase I; 13 U/mlRnase H. The reaction has halted by placement on ice and by addition of0.5 M EDTA (10 μl), then extracted through phenol:chloroform:isoamylalcohol (25:24:1, 150 μl). The aqueous phase was removed, collected anddiluted into 5M NaCl (15 μl) and absolute ethanol (−20° C., 400 μl) andcentrifuged for 2 minutes at 14,000×g. The supernatant was carefullyremoved from the resulting DNA pellet, the pellet resuspended in 70%ethanol (0.5 ml) and centrifuged again for 2 minutes at 14,000×g. Thesupernatant was again removed and the pellet dried in a speedvac.

[0217] Adapter Addition

[0218] The following reagents were added to the cDNA pellet from theSecond strand synthesis above, and the reaction was gently mixed andincubated at 16° C. for 16 hours: distilled water (25 μl); 5×T4 DNAligase buffer (10 μl); Sal I adapters (10 μl); T4 DNA ligase (5 μl). Thefinal composition of the reaction was the following: 50 mM Tris-HCl (pH7.6); 10 mM MgCl₂; 1 mM ATP; 5% (w/v) PEG 8000; 1 mM DTT; 200 μg/ml Sal1 adapters; 100 U/ml T4 DNA ligase. The reaction was extracted throughphenol:chloroform:isoamyl alcohol (25:24:1, 50 μl), the aqueous phaseremoved, collected and diluted into 5M NaCl (8 μl) and absolute ethanol(−20° C., 250 μl). This was then centrifuged for 20 minutes at 14,000×g,the supernatant removed and the pellet was resuspended in 0.5 ml 70%ethanol, and centrifuged again for 2 minutes at 14,000×g. Subsequently,the supernatant was removed and the resulting pellet dried in a speedvacand carried on into the next procedure.

[0219] Enzymatic Digestion:

[0220] To the cDNA prepared with the Sal 1 adapter from the previousparagraph was added the following reagents and the mixture was incubatedat 37° C. for 2 hours: DEPC-treated water (41 μl); Not 1 restrictionbuffer (REACT, Life Tech., 5 μl), Not 1 (4 μl). The final composition ofthis reaction was the following: 50 mM Tris-HCl (pH 8.0); 10 mM MgCl₂;100 mM MaCl; 1,200 U/ml Not 1.

[0221] Gel Isolation of cDNA:

[0222] The cDNA is size fractionated by acrylamide gel electrophoresison a 5% acrylamide gel, and any fragments which were larger than 1 Kb,as determined by comparison with a molecular weight marker, were excisedfrom the gel. The cDNA was then electroeluted from the gel into 0.1×TBEbuffer (200 μl) and extracted with phenol:chloroform:isoamyl alcohol(25:24:1, 200 μl). The aqueous phase was removed, collected andcentrifuged for 20 minutes at 14,000×g. The supernatant was removed fromthe DNA pellet which was resuspended in 70% ethanol (0.5 Ml) andcentrifuged again for 2 minutes at 14,000×g. The supernatant was againdiscarded, the pellet dried in a speedvac and resuspended in distilledwater (15 μl).

[0223] Ligation of cDNA into pRK5 Vector:

[0224] The following reagents were added together and incubated at 16°C. for 16 hours: 5×T4 ligase buffer (3 μl); pRK5, Xho1, Not1 digestedvector, 0.5 μg, 1 μl); cDNA prepared from previous paragraph (5 μl) anddistilled water (6 μl). Subsequently, additional distilled water (70 μl)and 10 mg/ml tRNA (0.1 μl) were added and the entire reaction wasextracted through phenol:chloroform:isoamyl alcohol (25:24:1). Theaqueous phase was removed, collected and diluted into Dumont 5M NaCl (10μl) and absolute ethanol (−20° C., 250 μl). This was then centrifugedfor 20 minutes at 14,000×g, decanted, and the pellet resuspended into70% ethanol (0.5 ml) and centrifuged again for 2 minutes at 14,000×g.The DNA pellet was then dried in a speedvac and eluted into distilledwater (3 μl) for use in the subsequent procedure.

[0225] Transformation of Library Ligation into Bacteria:

[0226] The ligated cDNA/pRK5 vector DNA prepared previously was chilledon ice to which was added electrocompetent DH10B bacteria (Life Tech.,20 μl). The bacteria vector mixture was then electroporated as per themanufacturers recommendation. Subsequently SOC media (1 ml) was addedand the mixture was incubated at 37° C. for 30 minutes. Thetransformants were then plated onto 20 standard 150 mm LB platescontaining ampicillin and incubated for 16 hours (370° C.) to allow thecolonies to grow. Positive colonies were then scraped off and the DNAisolated from the bacterial pellet using standard CsCl-gradientprotocols. For example, Ausubel et al., 2.3.1.

[0227] Identification of FLS 139

[0228] FLS139 can be identified in the human fetal liver library by anystandard method known in the art, including the methods reported byKlein R. D. et al. (1996), Proc. Natl. Acad. Sci. 93, 7108-7113 andJacobs (U.S. Pat. No. 5,563,637 issued Jul. 16, 1996). According toKlein et al. and Jacobs, cDNAs encoding novel secreted andmembrane-bound mammalian proteins are identified by detecting theirsecretory leader sequences using the yeast invertase gene as a reportersystem. The enzyme invertase catalyzes the breakdown of sucrose toglucose and fructose as well as the breakdown of raffinose to sucroseand melibiose. The secreted form of invertase is required for theutilization of sucrose by yeast (Saccharomyces cerevisiae) so that yeastcells that are unable to produce secreted invertase grow poorly on mediacontaining sucrose as the sole carbon and energy source. Both Klein R.D., supra, and Jacobs, supra, take advantage of the known ability ofmammalian signal sequences to functionally replace the native signalsequence of yeast invertase. A mammalian cDNA library is ligated to aDNA encoding a nonsecreted yeast invertase, the ligated DNA is isolatedand transformed into yeast cells that do not contain an invertase gene.Recombinants containing the nonsecreted yeast invertase gene ligated toa mammalian signal sequence are identified based upon their ability togrow on a medium containing only sucrose or only raffinose as the carbonsource. The mammalian signal sequences identified are then used toscreen a second, full-length cDNA library to isolate the full-lengthclones encoding the corresponding secreted proteins.

[0229] The nucleotide sequence of FLS139 in shown in FIG. 1-A (SEQ. ID.NO: 16), while its amino acid sequence is shown in FIG. 1-B (SEQ. ID.NO: 17). FLS139 contains a fibrinogen-like domain exhibiting a highdegree of sequence homology with the two known human ligands of theTIE-2 receptor (h-TIE2L1 and h-TIE2L2). Accordingly, FLS139 has beenidentified as a novel member of the TIE ligand family.

[0230] A clone of FLS139 was deposited with the American Type CultureCollection (ATCC), 12301 Parklawn Drive, Rockville, Md. 20852, on ______under the terms of the Budapest Treaty, and has been assigned thedeposit number ______.

EXAMPLE 1

[0231] Identification of NL1

[0232] NL1 was identified by screening the GenBank database using thecomputer program BLAST (Altshul et al., Methods in Enzymology266:460-480 (1996). The NL1 sequence shows homology with known expressedsequence tag (EST) sequences T35448, T11442, and W77823. None of theknown EST sequences have been identified as full length sequences, ordescribed as ligands associate 1d with the TIE receptors.

[0233] Following its identification, NL1 was cloned from a human fetallung library prepared from mRNA purchased from Clontech, Inc. (PaloAlto, Calif., USA), catalog # 6528-1, following the manufacturer'sinstructions. The library was screened by hybridization with syntheticoligonucleotide probes: NL1.5-1 5′-GCTGACGAACCAAGGCAACTACAAACTCCTGGTSEQ. ID. NO: 7 NL1.3-1 5′-TGCGGCCGGACCAGTCCTCCATGGTCACCAGGAGTTTGTAG SEQ.ID. NO: 8 NL1.3-2 5′-GGTGGTGAACTGCTTGCCGTTGTGCCATGTAAA SEQ. ID. NO: 9

[0234] based on the ESTs found in the GenBank database. cDNA sequenceswere sequenced in their entireties.

[0235] The nucleotide and amino acid sequences of NL1 are shown in FIG.2 (SEQ. ID. NO: 1) and FIG. 3 (SEQ. ID. NO: 2), respectively.

[0236] NL1 shows a 23% sequence identity with both the TIE1 and the TIE2ligand.

[0237] A clone of NL1 was deposited with the American Type CultureCollection (ATCC), 12301 Parklawn Drive, Rockville, Md. 20852, on ______under the terms of the Budapest Treaty, and has been assigned thedeposit number ______.

EXAMPLE 2

[0238] Identification of NL5 and NL8

[0239] An expressed sequence tag (EST) DNA database (LIFESEQ™, IncytePharmaceuticals, Palo Alto, Calif.) was searched and ESTs wereidentified that showed homology to the FLS 139 protein of ReferenceExample 1. To clone NL5 and NL8, a human fetal lung library preparedfrom mRNA purchased from Clontech, Inc. (Palo Alto, Calif., USA),catalog # 6528-1 was used, following the manufacturer's instructions.The library was screened by hybridization with synthetic oligonucleotideprobes:

[0240] NL5 NL5 SEQ. ID. NO: 10 NL5.5-1 5′ CAGGTTATCCCAGAGATTTAATGCCACCASEQ. ID. NO: 11 NL5.3-1 5′ TTGGTGGGAGAAGTTGCCAGATCAGGTGGTGGCA SEQ. ID.NO: 12 NL5.3-2 5′ TTCACACCATAACTGCATTGGTCCA NL8 SEQ. ID. NO: 13 NL8.5-15′ ACGTAGTTCCAGTATGGTGTGAGCAGCAACTGGA SEQ. ID. NO: 14 NL8.3-15′ AGTCCAGCCTCCACCCTCCAGTTGCT SEQ. ID. NO: 15 NL8.3-25′ CCCCAGTCCTCCAGGAGAACCAGCA

[0241] based on the ESTs found in the database. cDNA sequences weresequenced in their entireties. cDNA clones were sequenced. The entirenucleotide and deduced amino acid sequences of NL5 are shown in FIGS. 4and 5 (SEQ. ID. Nos. 3 and 4). The entire nucleotide and deduced aminoacid sequences of NL8 are shown in FIGS. 6 and 7 (SEQ. ID. Nos: 5 and6).

[0242] Based on a BLAST and FastA sequence alignment analysis (using theALIGN program) of the full-length sequences, NL5 shows a 24% sequenceidentity with both ligand 1 and ligand 2 of the TIE2 receptor. NL8 showsa 23% sequence identity with both ligand 1 and ligand 2 of the TIE2receptor.

[0243] The fibrinogen domains of the TIE ligands NL1, NL5 and NL8 are64-74% identical. More specifically, the fibrinogen domain of NL1 is 74%identical with the fibrinogen domain of NL5 and 63% identical with thefibrinogen domain of NL8, while the fibrinogen domain of NL5 is 57%identical with the fibrinogen domain of NL8. Ligand 1 and ligand 2 ofthe TIE-2 receptor are 64% identical and 4043% identical to NL1, NL5 andNL8.

EXAMPLE 3

[0244] Northern Blot and in situ RNA Hybridization Analysis

[0245] Expression of the NL1 and NL5 mRNA in human tissues was examinedby Northern blot analysis. Human mRNA blots were hybridized to a³²P-labeled DNA probe based on the full length cDNAs; the probes weregenerated by digesting and purifying the cDNA inserts. Human fetal RNAblot MTN (Clontech) and human adult RNA blot MTN-II (Clontech) wereincubated with the DNA probes. Blots were incubated with the probes inhybridization buffer (5×SSPE; 2Denhardt's solution; 100 mg/mL denaturedsheared salmon sperm DNA; 50% formamide; 2% SDS) for 60 hours at 42° C.The blots were washed several times in 2×SSC; 0.05% SDS for 1 hour atroom temperature, followed by a 30 minute wash in 0.1×SSC; 0.1% SDS at50° C. The blots were developed after overnight exposure byphosphorimager analysis (Fuji).

[0246] As shown in FIGS. 11 and 12, NL1 and NL5 mRNA transcripts weredetected. Strong NL1 mRNA expression was detected in heart and skeletalmuscle tissue and in the pancreas. NL5 mRNA was strongly expressed inskeletal muscle, and, to a lesser degree, heart, placenta and pancreas.

[0247] In situ hybridization results show that NL1 is expressed in thecartilage of developing long bones and in periosteum adjacent todifferentiating osteoblasts. Expression was also observed in connectivetissue at sites of synovial joint formation, in connective tissue septa,and in the periosteum of fetal body wall (FIGS. 8-A and 8-B).

[0248] In situ hybridization was performed using an optimized protocol,using PCR-generated ³³P-labeled riboprobes. (Lu and Gillett, Cell Vision1: 169-176 (1994)). Formalin-fixed, paraffin-embedded human fetal andadult tissues were sectioned, deparaffinized, deproteinated inproteinase K (20 g/ml) for 15 minutes at 37° C., and further processedfor in situ hybridization as described by Lu and Gillett (1994). A[³³-P] UTP-labeled antisense riboprobe was generated from a PCR productand hybridized at 55° C. overnight. The slides were dipped in Kodak NTB2nuclear track emulsion and exposed for 4 weeks.

[0249] In situ hybridization indicated NL5 mRNA expression in adulthuman breast cancel cells over benign breast epithelium, areas ofapocrine metaplasia and sclerosing adenosis. Expression was furtherobserved over infiltrating breast ductal carcinoma cells. In fetal lowerlimb tissue, high expression was found at sites of enchondral boneformation, in osteocytes and in periosteum/perichondrium of developingbones. NL5 mRNA was also highly expressed in osteocytes and inperiosteum/periochondrium of developing bones of fetal body wall tissue.This distribution suggests a role in bone formation and differentiation(FIGS. 9-A and 9-B).

[0250] In situ hybridization for NL8 showed highly organized expressionpattern in the developing limb, intestine and body wall, suggesting adistinctive functional role at this site, and potential involvement inangiogenesis and patterning (FIGS. 10-A and 10-B). This expressionpattern is distinct from that of NL1 and NL5.

EXAMPLE 4

[0251] Expression of NL1, NL5, and NL8 in E. coli

[0252] This example illustrates the preparation of an unglycosylatedform of the TIE ligands of the present invention in E. coli. The DNAsequence encoding a NL1, NL5 or NL8 ligand (SEQ. ID. NOs: 1, 3, and 5,respectively) is initially amplified using selected PCR primers. Theprimers should contain restriction enzyme sites which correspond to therestriction enzyme sites on the selected expression vector. A variety ofexpression vectors may be employed. The vector will preferably encode anantibiotic resistance gene, an origin of replication, e promoter, and aribozyme binding site. An example of a suitable vector is pBR322(derived from E. coli; see Bolivar et al., Gene 2:95 (1977)) whichcontains genes for ampicillin and tetracycline resistance. The vector isdigested with restriction enzyme and dephosphorylated. The PCR amplifiedsequences are then ligated into the vector.

[0253] The ligation mixture is then used to transform a selected E. colistrain, using the methods described in Sambrook et al., supra.Transformants are identified by their ability to grow on LB plates andantibiotic resistant colonies are then selected. Plasmid DNA can beisolated and confirmed by restriction analysis.

[0254] Selected clones can be grown overnight in liquid culture mediumsuch as 1B broth supplemented with antibiotics. The overnight culturemay subsequently be used to inoculate a later scale culture. The cellsare then grown to a desired optical density. An inducer, such as IPTGmay be added.

[0255] After culturing the cells for several more hours, the cells canbe harvested by centrifugation. The cell pellet obtained by thecentrifugation can be solubilized using various agents known in the art,and the solubilized protein can then be purified using a metal chelatingcolumn under conditions that allow tight binding of the protein.

EXAMPLE 5

[0256] Expression of NL1, NL5 and NL8 in Mammalian Cells

[0257] This example illustrates preparation of a glycosylated form ofthe NL1, NL5 and NL8 ligands by recombinant expression in mammaliancells.

[0258] The vector, pRK5 (see EP 307,247, published Mar. 15, 1989), isemployed as the expression vector. Optionally, the NL1, NL5 and NL8 DNAis ligated into pRK5 with selected restriction enzymes to allowinsertion of the NL1, NL5 and NL8 DNA using ligation methods such asdescribed in Sambrook et al., supra. The resulting vector is calledpRK5-NL1, NL5 and NL8, respectively.

[0259] In one embodiment, the selected host cells may be 293 cells.Human 293 cells (ATCC CCL 1573) are grown to confluence in tissueculture plates in medium such as DMEM supplemented with fetal calf serumand optionally, nutrient components and/or antibiotics. About 10 μgpRK5-NL1, NL5 and NL8 DNA is mixed with about 1 μg DNA encoding the VARNA gene [Thimmappaya et al., Cell, 31:543 (1982)] and dissolved in 500μl of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl₂. To this mixture isadded, dropwise, 500 μl of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mMNaPO₄, and a precipitate is allowed to form for 10 minutes at 25° C. Theprecipitate is suspended and added to the 293 cells and allowed tosettle for about four hours at 37° C. The culture medium is aspiratedoff and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293cells are then washed with serum free medium, fresh medium is added andthe cells are incubated for about 5 days.

[0260] Approximately 24 hours after the transfections, the culturemedium is removed and replaced with culture medium (alone) or culturemedium containing 200 μCi/ml ³⁵S-cysteine and 200 μCi/ml ³⁵S-methionine.After a 12 hour incubation, the conditioned medium is collected,concentrated on a spin filter, and loaded onto a 15% SDS gel. Theprocessed gel may be dried and exposed to film for a selected period oftime to reveal the presence of NL1, NL5 and NL8 polypeptide. Thecultures containing transfected cells may undergo further incubation (inserum free medium) and the medium is tested in selected bioassays.

[0261] In an alternative technique, NL1, NL5 and NL8 may be introducedinto 293 cells transiently using the dextran sulfate method described bySomparyrac et al., Proc. Natl. Acad. Sci., 12:7575 (1981). 293 cells aregrown to maximal density in a spinner flask and 700 μg pRK5-NL1, NL5 andNL8 DNA is added. The cells are first concentrated from the spinnerflask by centrifugation and washed with PBS. The DNA-dextran precipitateis incubated on the cell pellet for four hours. The cells are treatedwith 20% glycerol for 90 seconds, washed with tissue culture medium, andreintroduced into the spinner flask containing tissue culture medium, 5μg/ml bovine insulin and 0.1 μg/ml bovine transferrin. After about fourdays, the conditioned media is centrifuged and filtered to remove cellsand debris. The sample containing expressed NL1, NL5 and NL8 can then beconcentrated and purified by any selected method, such as dialysisand/or column chromatography.

[0262] In another embodiment, NL1, NL5 and NL8 can be expressed in CHOcells. The pRK5-NL1, NL5 and NL8 can be transfected into CHO cells usingknown reagents such as CaPO₄ or DEAE-dextran. As described above, thecell cultures can be incubated, and the medium replaced with culturemedium (alone) or medium containing a radiolabel such as ³⁵S-methionine.After determining the presence of NL1, NL5 and NL8 polypeptide, theculture medium may be replaced with serum free medium. Preferably, thecultures are incubated for about 6 days, and then the conditioned mediumis harvested. The medium containing the expressed NL1, NL5 and NL8 canthen be concentrated and purified by any selected method.

[0263] Epitope-tagged NL1, NL5 and NL8 may also be expressed in host CHOcells. NL1, NL5 and NL8 may be subcloned out of the pRK5 vector. Thesubclone insert can undergo PCR to fuse in frame with a selected epitopetag such as a poly-his tag into a Baculovirus expression vector. Thepoly-his tagged NL1, NL5 and NL8 insert can then be subcloned into aSV40 driven vector containing a selection marker such as DHFR forselection of stable clones. Finally, the CHO cells can be transfected(as described above) with the SV40 driven vector. Labeling may beperformed, as described above, to verify expression. The culture mediumcontaining the expressed poly-His tagged NL1, NL5 and NL8 can then beconcentrated and purified by any selected method, such as byNi²⁺-chelate affinity chromatography.

EXAMPLE 6

[0264] Expression of NL1, NL5 and NL8 in Yeast

[0265] First, yeast expression vectors are constructed for intracellularproduction or secretion of NL1, NL5 and NL8 from the ADH2/GAPDHpromoter. DNA encoding NL1, NL5 and NL8, a selected signal peptide andthe promoter is inserted into suitable restriction enzyme sites in theselected plasmid to direct intracellular expression of NL1, NL5 and NL8.For secretion, DNA encoding NL1, NL5 and NL8 can be cloned into theselected plasmid, together with DNA encoding the ADH2/GAPDH promoter,the yeast alpha-factor secretory signal/leader sequence, and linkersequences (if needed) for expression of NL1, NL5 and NL8.

[0266] Yeast cells, such as yeast strain AB 110, can then be transformedwith the expression plasmids described above and cultured in selectedfermentation media. The transformed yeast supernatants can be analyzedby precipitation with 10% trichloroacetic acid and separation bySDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

[0267] Recombinant NL1, NL5 and NL8 can subsequently be isolated andpurified by removing the yeast cells from the fermentation medium bycentrifugation and then concentrating the medium using selectedcartridge filters. The concentrate containing NL1, NL5 and NL8 mayfurther be purified using selected column chromatography resins.

EXAMPLE 7

[0268] Expression of NL1, NL2 and NL8 in Baculovirus

[0269] The following method describes recombinant expression of NL1, NL5and NL8 in Baculovirus.

[0270] The NL1, NL5 and NL8 is fused upstream of an epitope tagcontained with a baculovirus expression vector. Such epitope tagsinclude poly-his tags and immunoglobulin tags (like Fc regions of IgG).A variety of plasmids may be employed, including plasmids derived fromcommercially available plasmids such as pVL1393 (Novagen). Briefly, theNL1, NL5 and NL8 or the desired portion of the NL1, NL5 and NL8 (such asthe sequence encoding the extracellular domain of a transmembraneprotein) is amplified by PCR with primers complementary to the 5′ and 3′regions. The 5′ primer may incorporate flanking (selected) restrictionenzyme sites. The product is then digested with those selectedrestriction enzymes and subcloned into the expression vector.

[0271] Recombinant baculovirus is generated by co-transfecting the aboveplasmid and BaculoGold™ virus DNA (Pharmingen) into Spodopterafrugiperda (“Sf9”) cells (ATCC CRL 1711) using lipofectin (commerciallyavailable from GIBCO-BRL). After 4-5 days of incubation at 28° C., thereleased viruses are harvested and used for further amplifications.Viral infection and protein expression is performed as described byO'Reilley et al., Baculovirus expression vectors: A laboratory Manual,Oxford: Oxford University Press (1994).

[0272] Expressed poly-his tagged NL1, NL5 and NL8 can then be purified,for example, by Ni²⁺-chelate affinity chromatography as follows.Extracts are prepared from recombinant virus-infected Sf9 cells asdescribed by Rupert et al., Nature, 362:175-179 (1993). Briefly, Sf9cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9;12.5 mM MgCl₂; 0.1 mM EDTA; 10% Glycerol; 0.1% NP-40; 0.4 M KCl), andsonicated twice for 20 seconds on ice. The sonicates are cleared bycentrifugation, and the supernatant is diluted 50-fold in loading buffer(50 mM phosphate, 300 mM NaCl, 10% Glycerol, pH 7.8) and filteredthrough a 0.45 μm filter. A Ni²⁺-NTA agarose column (commerciallyavailable from Qiagen) is prepared with a bed volume of 5 mL, washedwith 25 mL of water and equilibrated with 25 mL of loading buffer. Thefiltered cell extract is loaded onto the column at 0.5 mL per minute.The column is washed to baseline A₂₈₀ with loading buffer, at whichpoint fraction collection is started. Next, the column is washed with asecondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% Glycerol, pH6.0), which elutes nonspecifically bound protein. After reaching A₂₈₀baseline again, the column is developed with a 0 to 500 mM Imidazolegradient in the secondary wash buffer. One mL fractions are collectedand analyzed by SDS-PAGE and silver staining or western blot withNi²⁺-NTA-conjugated to alkaline phosphatase (Qiagen). Fractionscontaining the eluted His₁₀-tagged NL1, NL5 and NL8 are pooled anddialyzed against loading buffer.

[0273] Alternatively, purification of the IgG tagged (or Fc tagged) NL1,NL5 and NL8 can be performed using known chromatography techniques,including for instance, Protein A or protein G column chromatography.

EXAMPLE 8

[0274] Preparation of Antibodies that bind NL1, NL2 and NL8

[0275] This example illustrates preparation of monoclonal antibodieswhich can specifically bind NL1, NL2 and NL8.

[0276] Techniques for producing the monoclonal antibodies are known inthe art and are described, for example, in Goding, supra. Immunogensthat may be employed include purified ligands of the present invention,fusion proteins containing such ligands, and cells expressingrecombinant ligands on the cell surface. Selection of the immunogen canbe made by the skilled artisan without undue experimentation.

[0277] Mice, such as Balb/c, are immunized with the immunogen emulsifiedin complete Freund's adjuvant and injected subcutaneously orintraperitoneally in an amount from 1-100 micrograms. Alternatively, theimmunogen is emulsified in MPL-TDM adjuvant (Ribi ImmunochemicalResearch, Hamilton, Mont.) and injected into the animal's hind foodpads. The immunized mice are then boosted 10 to 12 days later withadditional immunogen emulsified in the selected adjuvant. Thereafter,for several weeks, the mice might also be boosted with additionalimmunization injections. Serum samples may be periodically obtained fromthe mice by retro-orbital bleeding for testing ELISA assays to detectthe antibodies.

[0278] After a suitable antibody titer has been detected, the animals“positive” for antibodies can be injected with a final intravenousinjection of the given ligand. Three to four days later, the mice aresacrificed and the spleen cells are harvested. The spleen cells are thenfused (using 35% polyethylene glycol) to a selected murine myeloma cellline such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusionsgenerate hybridoma cells which can then be plated in 96 well tissueculture plates containing HAT (hypoxanthine, aminopterin, and thymidine)medium to inhibit proliferation of non-fused cells, myeloma hybrids, andspleen cell hybrids.

[0279] The hybridoma cells will be screened in an ELISA for reactivityagainst the antigen. Determination of “positive” hybridoma cellssecreting the desired monoclonal antibodies against the TIE ligandsherein is well within the skill in the art.

[0280] The positive hybridoma cells can be injected intraperitoneal intosyngeneic Balb/c mice to produce ascites containing the anti-TIE-ligandmonoclonal antibodies. Alternatively, the hybridoma cells can be grownin tissue culture flasks or roller bottles. Purification of themonoclonal antibodies produced in the ascites can be accomplished usingammonium sulfate precipitation, followed by gel exclusionchromatography. Alternatively, affinity chromatography based uponbinding of antibody to protein A or protein G can be employed.

[0281] Deposit of Material

[0282] As noted before, the following materials have been deposited withthe American Type Culture Collection, 12301 Parklawn Drive, Rockville,Md., USA (ATCC): Material ATCC Dep. No. Deposit Date NL1-DNA 22779-1130NL5-DNA 28497-1130 NL8-DNA 23339-1130

[0283] These deposits were made under the provisions of the BudapestTreaty on the International Recognition of the Deposit of Microorganismsfor the Purpose of Patent Procedure and the Regulations thereunder(Budapest Treaty). This assures maintenance of a viable culture of thedeposit for 30 years from the date of the deposit. The deposit will bemade available by ATCC under the terms of the Budapest Treaty, andsubject to an agreement between Genentech, Inc. and ATCC, which assurespermanent and unrestricted availability of the progeny of the culture ofthe deposit to the public upon issuance of the pertinent U.S. patent orupon laying open to the public of any U.S. or foreign patentapplication, whichever comes first, and assures availability of theprogeny to one determined by the U.S. Commissioner of Patents andTrademarks to be entitled thereto according to 35 USC §122 andCommissioner's rules pursuant thereto (including 37 C.F.R. §1.14 withparticular reference to 886 OG 683).

[0284] The assignee of the present application has agreed that if aculture of the materials on deposit should die ot be lost or destroyedwhen cultivated under suitable conditions, the materials will bepromptly replaced on notification with another of the same. Availabilityof the deposited material is not to be construed as a license topractice the invention in contravention of the rights granted under theauthority of any government in accordance with its patent laws.

[0285] The present specification is considered to be sufficient toenable one skilled in the art to practice the invention. The presentinvention is not to be limited in scope by the construct deposited,since the deposited embodiment is intended as a single illustration ofcertain aspects of the invention and any constructs that arefunctionally equivalent are within the scope of the invention. Thedeposit of material herein does not constitute an admission that thewritten description is inadequate to enable the practice of any aspectof the invention, including the best more thereof, nor is it to beconstrued as limiting the scope of the claims to the specificillustrations that it represents. Indeed, various modifications of theinvention in addition to those shown and described herein will becomeapparent to those skilled in the art from the foregoing description andfall within the scope of the appended claims.

1 17 2290 base pairs Nucleic Acid Single Linear 1 GGCTGAGGGG AGGCCCGGAGCCTTTCTGGG GCCTGGGGGA TCCTCTTGCA 50 CTGGTGGGTG GAGAGAAGCG CCTGCAGCCAACCAGGGTCA GGCTGTGCTC 100 ACAGTTTCCT CTGGCGGCAT GTAAAGGCTC CACAAAGGAGTTGGGAGTTC 150 AAATGAGGCT GCTGCGGACG GCCTGAGGAT GGACCCCAAG CCCTGGACCT200 GCCGAGCGTG GCACTGAGGC AGCGGCTGAC GCTACTGTGA GGGAAAGAAG 250GTTGTGAGCA GCCCCGCAGG ACCCCTGGCC AGCCCTGGCC CCAGCCTCTG 300 CCGGAGCCCTCTGTGGAGGC AGAGCCAGTG GAGCCCAGTG AGGCAGGGCT 350 GCTTGGCAGC CACCGGCCTGCAACTCAGGA ACCCCTCCAG AGGCCATGGA 400 CAGGCTGCCC CGCTGACGGC CAGGGTGAAGCATGTGAGGA GCCGCCCCGG 450 AGCCAAGCAG GAGGGAAGAG GCTTTCATAG ATTCTATTCACAAAGAATAA 500 CCACCATTTT GCAAGGACCA TGAGGCCACT GTGCGTGACA TGCTGGTGGC550 TCGGACTGCT GGCTGCCATG GGAGCTGTTG CAGGCCAGGA GGACGGTTTT 600GAGGGCACTG AGGAGGGCTC GCCAAGAGAG TTCATTTACC TAAACAGGTA 650 CAAGCGGGCGGGCGAGTCCC AGGACAAGTG CACCTACACC TTCATTGTGC 700 CCCAGCAGCG GGTCACGGGTGCCATCTGCG TCAACTCCAA GGAGCCTGAG 750 GTGCTTCTGG AGAACCGAGT GCATAAGCAGGAGCTAGAGC TGCTCAACAA 800 TGAGCTGCTC AAGCAGAAGC GGCAGATCGA GACGCTGCAGCAGCTGGTGG 850 AGGTGGACGG CGGCATTGTG AGCGAGGTGA AGCTGCTGCG CAAGGAGAGC900 CGCAACATGA ACTCGCGGGT CACGCAGCTC TACATGCAGC TCCTGCACGA 950GATCATCCGC AAGCGGGACA ACGCGTTGGA GCTCTCCCAG CTGGAGAACA 1000 GGATCCTGAACCAGACAGCC GACATGCTGC AGCTGGCCAG CAAGTACAAG 1050 GACCTGGAGC ACAAGTACCAGCACCTGGCC ACACTGGCCC ACAACCAATC 1100 AGAGATCATC GCGCAGCTTG AGGAGCACTGCCAGAGGGTG CCCTCGGCCA 1150 GGCCCGTCCC CCAGCCACCC CCCGCTGCCC CGCCCCGGGTCTACCAACCA 1200 CCCACCTACA ACCGCATCAT CAACCAGATC TCTACCAACG AGATCCAGAG1250 TGACCAGAAC CTGAAGGTGC TGCCACCCCC TCTGCCCACT ATGCCCACTC 1300TCACCAGCCT CCCATCTTCC ACCGACAAGC CGTCGGGCCC ATGGAGAGAC 1350 TGCCTGCAGGCCCTGGAGGA TGGCCACGAC ACCAGCTCCA TCTACCTGGT 1400 GAAGCCGGAG AACACCAACCGCCTCATGCA GGTGTGGTGC GACCAGAGAC 1450 ACGACCCCGG GGGCTGGACC GTCATCCAGAGACGCCTGGA TGGCTCTGTT 1500 AACTTCTTCA GGAACTGGGA GACGTACAAG CAAGGGTTTGGGAACATTGA 1550 CGGCGAATAC TGGCTGGGCC TGGAGAACAT TTACTGGCTG ACGAACCAAG1600 GCAACTACAA ACTCCTGGTG ACCATGGAGG ACTGGTCCGG CCGCAAAGTC 1650TTTGCAGAAT ACGCCAGTTT CCGCCTGGAA CCTGAGAGCG AGTATTATAA 1700 GCTGCGGCTGGGGCGCTACC ATGGCAATGC GGGTGACTCC TTTACATGGC 1750 ACAACGGCAA GCAGTTCACCACCCTGGACA GAGATCATGA TGTCTACACA 1800 GGAAACTGTG CCCACTACCA GAAGGGAGGCTGGTGGTATA ACGCCTGTGC 1850 CCACTCCAAC CTCAACGGGG TCTGGTACCG CGGGGGCCATTACCGGAGCC 1900 GCTACCAGGA CGGAGTCTAC TGGGCTGAGT TCCGAGGAGG CTCTTACTCA1950 CTCAAGAAAG TGGTGATGAT GATCCGACCG AACCCCAACA CCTTCCACTA 2000AGCCAGCTCC CCCTCCTGAC CTCTCGTGGC CATTGCCAGG AGCCCACCCT 2050 GGTCACGCTGGCCACAGCAC AAAGAACAAC TCCTCACCAG TTCATCCTGA 2100 GGCTGGGAGG ACCGGGATGCTGGATTCTGT TTTCCGAAGT CACTGCAGCG 2150 GATGATGGAA CTGAATCGAT ACGGTGTTTTCTGTCCCTCC TACTTTCCTT 2200 CACACCAGAC AGCCCCTCAT GTCTCCAGGA CAGGACAGGACTACAGACAA 2250 CTCTTTCTTT AAATAAATTA AGTCTCTACA ATAAAAAAAA 2290 493amino acids Amino Acid Linear 2 Met Arg Pro Leu Cys Val Thr Cys Trp TrpLeu Gly Leu Leu Ala 1 5 10 15 Ala Met Gly Ala Val Ala Gly Gln Glu AspGly Phe Glu Gly Thr 20 25 30 Glu Glu Gly Ser Pro Arg Glu Phe Ile Tyr LeuAsn Arg Tyr Lys 35 40 45 Arg Ala Gly Glu Ser Gln Asp Lys Cys Thr Tyr ThrPhe Ile Val 50 55 60 Pro Gln Gln Arg Val Thr Gly Ala Ile Cys Val Asn SerLys Glu 65 70 75 Pro Glu Val Leu Leu Glu Asn Arg Val His Lys Gln Glu LeuGlu 80 85 90 Leu Leu Asn Asn Glu Leu Leu Lys Gln Lys Arg Gln Ile Glu Thr95 100 105 Leu Gln Gln Leu Val Glu Val Asp Gly Gly Ile Val Ser Glu Val110 115 120 Lys Leu Leu Arg Lys Glu Ser Arg Asn Met Asn Ser Arg Val Thr125 130 135 Gln Leu Tyr Met Gln Leu Leu His Glu Ile Ile Arg Lys Arg Asp140 145 150 Asn Ala Leu Glu Leu Ser Gln Leu Glu Asn Arg Ile Leu Asn Gln155 160 165 Thr Ala Asp Met Leu Gln Leu Ala Ser Lys Tyr Lys Asp Leu Glu170 175 180 His Lys Tyr Gln His Leu Ala Thr Leu Ala His Asn Gln Ser Glu185 190 195 Ile Ile Ala Gln Leu Glu Glu His Cys Gln Arg Val Pro Ser Ala200 205 210 Arg Pro Val Pro Gln Pro Pro Pro Ala Ala Pro Pro Arg Val Tyr215 220 225 Gln Pro Pro Thr Tyr Asn Arg Ile Ile Asn Gln Ile Ser Thr Asn230 235 240 Glu Ile Gln Ser Asp Gln Asn Leu Lys Val Leu Pro Pro Pro Leu245 250 255 Pro Thr Met Pro Thr Leu Thr Ser Leu Pro Ser Ser Thr Asp Lys260 265 270 Pro Ser Gly Pro Trp Arg Asp Cys Leu Gln Ala Leu Glu Asp Gly275 280 285 His Asp Thr Ser Ser Ile Tyr Leu Val Lys Pro Glu Asn Thr Asn290 295 300 Arg Leu Met Gln Val Trp Cys Asp Gln Arg His Asp Pro Gly Gly305 310 315 Trp Thr Val Ile Gln Arg Arg Leu Asp Gly Ser Val Asn Phe Phe320 325 330 Arg Asn Trp Glu Thr Tyr Lys Gln Gly Phe Gly Asn Ile Asp Gly335 340 345 Glu Tyr Trp Leu Gly Leu Glu Asn Ile Tyr Trp Leu Thr Asn Gln350 355 360 Gly Asn Tyr Lys Leu Leu Val Thr Met Glu Asp Trp Ser Gly Arg365 370 375 Lys Val Phe Ala Glu Tyr Ala Ser Phe Arg Leu Glu Pro Glu Ser380 385 390 Glu Tyr Tyr Lys Leu Arg Leu Gly Arg Tyr His Gly Asn Ala Gly395 400 405 Asp Ser Phe Thr Trp His Asn Gly Lys Gln Phe Thr Thr Leu Asp410 415 420 Arg Asp His Asp Val Tyr Thr Gly Asn Cys Ala His Tyr Gln Lys425 430 435 Gly Gly Trp Trp Tyr Asn Ala Cys Ala His Ser Asn Leu Asn Gly440 445 450 Val Trp Tyr Arg Gly Gly His Tyr Arg Ser Arg Tyr Gln Asp Gly455 460 465 Val Tyr Trp Ala Glu Phe Arg Gly Gly Ser Tyr Ser Leu Lys Lys470 475 480 Val Val Met Met Ile Arg Pro Asn Pro Asn Thr Phe His 485 490493 3355 base pairs Nucleic Acid Single Linear 3 GCAGCTGGTT ACTGCATTTCTCCATGTGGC AGACAGAGCA AAGCCACAAC 50 GCTTTCTCTG CTGGATTAAA GACGGCCCACAGACCAGAAC TTCCACTATA 100 CTACTTAAAA TTACATAGGT GGCTTGTCAA ATTCAATTGATTAGTATTGT 150 AAAAGGAAAA AGAAGTTCCT TCTTACAGCT TGGATTCAAC GGTCCAAAAC200 AAAAATGCAG CTGCCATTAA AGTCTCAGAT GAACAAACTT CTACACTGAT 250TTTTAAAATC AAGAATAAGG GCAGCAAGTT TCTGGATTCA CTGAATCAAC 300 AGACACAAAAAGCTGGCAAT ATAGCAACTA TGAAGAGAAA AGCTACTAAT 350 AAAATTAACC CAACGCATAGAAGACTTTTT TTTCTCTTCT AAAAACAACT 400 AAGTAAAGAC TTAAATTTAA ACACATCATTTTACAACCTC ATTTCAAAAT 450 GAAGACTTTT ACCTGGACCC TAGGTGTGCT ATTCTTCCTACTAGTGGACA 500 CTGGACATTG CAGAGGTGGA CAATTCAAAA TTAAAAAAAT AAACCAGAGA550 AGATACCCTC GTGCCACAGA TGGTAAAGAG GAAGCAAAGA AATGTGCATA 600CACATTCCTG GTACCTGAAC AAAGAATAAC AGGGCCAATC TGTGTCAACA 650 CCAAGGGGCAAGATGCAAGT ACCATTAAAG ACATGATCAC CAGGATGGAC 700 CTTGAAAACC TGAAGGATGTGCTCTCCAGG CAGAAGCGGG AGATAGATGT 750 TCTGCAACTG GTGGTGGATG TAGATGGAAACATTGTGAAT GAGGTAAAGC 800 TGCTGAGAAA GGAAAGCCGT AACATGAACT CTCGTGTTACTCAACTCTAT 850 ATGCAATTAT TACATGAGAT TATCCGTAAG AGGGATAATT CACTTGAACT900 TTCCCAACTG GAAAACAAAA TCCTCAATGT CACCACAGAA ATGTTGAAGA 950TGGCAACAAG ATACAGGGAA CTAGAGGTGA AATACGCTTC CTTGACTGAT 1000 CTTGTCAATAACCAATCTGT GATGATCACT TTGTTGGAAG AACAGTGCTT 1050 GAGGATATTT TCCCGACAAGACACCCATGT GTCTCCCCCA CTTGTCCAGG 1100 TGGTGCCACA ACATATTCCT AACAGCCAACAGTATACTCC TGGTCTGCTG 1150 GGAGGTAACG AGATTCAGAG GGATCCAGGT TATCCCAGAGATTTAATGCC 1200 ACCACCTGAT CTGGCAACTT CTCCCACCAA AAGCCCTTTC AAGATACCAC1250 CGGTAACTTT CATCAATGAA GGACCATTCA AAGACTGTCA GCAAGCAAAA 1300GAAGCTGGGC ATTCGGTCAG TGGGATTTAT ATGATTAAAC CTGAAAACAG 1350 CAATGGACCAATGCAGTTAT GGTGTGAAAA CAGTTTGGAC CCTGGGGGTT 1400 GGACTGTTAT TCAGAAAAGAACAGACGGCT CTGTCAACTT CTTCAGAAAT 1450 TGGGAAAATT ATAAGAAAGG GTTTGGAAACATTGACGGAG AATACTGGCT 1500 TGGACTGGAA AATATCTATA TGCTTAGCAA TCAAGATAATTACAAGTTAT 1550 TGATTGAATT AGAAGACTGG AGTGATAAAA AAGTCTATGC AGAATACAGC1600 AGCTTTCGTC TGGAACCTGA AAGTGAATTC TATAGACTGC GCCTGGGAAC 1650TTACCAGGGA AATGCAGGGG ATTCTATGAT GTGGCATAAT GGTAAACAAT 1700 TCACCACACTGGACAGAGAT AAAGATATGT ATGCAGGAAA CTGCGCCCAC 1750 TTTCATAAAG GAGGCTGGTGGTACAATGCC TGTGCACATT CTAACCTAAA 1800 TGGAGTATGG TACAGAGGAG GCCATTACAGAAGCAAGCAC CAAGATGGAA 1850 TTTTCTGGGC CGAATACAGA GGCGGGTCAT ACTCCTTAAGAGCAGTTCAG 1900 ATGATGATCA AGCCTATTGA CTGAAGAGAG ACACTCGCCA ATTTAAATGA1950 CACAGAACTT TGTACTTTTC AGCTCTTAAA AATGTAAATG TTACATGTAT 2000ATTACTTGGC ACAATTTATT TCTACACAGA AAGTTTTTAA AATGAATTTT 2050 ACCGTAACTATAAAAGGGAA CCTATAAATG TAGTTTCATC TGTCGTCAAT 2100 TACTGCAGAA AATTATGTGTATCCACAACC TAGTTATTTT AAAAATTATG 2150 TTGACTAAAT ACAAAGTTTG TTTTCTAAAATGTAAATATT TGCCACAATG 2200 TAAAGCAAAT CTTAGCTATA TTTTAAATCA TAAATAACATGTTCAAGATA 2250 CTTAACAATT TATTTAAAAT CTAAGATTGC TCTAACGTCT AGTGAAAAAA2300 ATATTTTTTA AATTTCAGCC AAATAATGCA TTTTATTTTA TAAAAATACA 2350GACAGAAAAT TAGGGAGAAA CTTCTAGTTT TGCCAATAGA AAATGTTCTT 2400 CCATTGAATAAAAGTTATTT CAAATTGAAT TTGTGCCTTT CACACGTAAT 2450 GATTAAATCT GAATTCTTAATAATATATCC TATGCTGATT TTCCCAAAAC 2500 ATGACCCATA GTATTAAATA CATATCATTTTTAAAAATAA AAAAAAACCC 2550 AAAAATAATG CATGCATAAT TTAAATGGTC AATTTATAAAGACAAATCTA 2600 TGAATGAATT TTTCAGTGTT ATCTTCATAT GATATGCTGA ACACCAAAAT2650 CTCCAGAAAT GCATTTTATG TAGTTCTAAA ATCAGCAAAA TATTGGTATT 2700ACAAAAATGC AGAATATTTA GTGTGCTACA GATCTGAATT ATAGTTCTAA 2750 TTTATTATTACTTTTTTTCT AATTTACTGA TCTTACTACT ACAAAGAAAA 2800 AAAAACCCAA CCCATCTGCAATTCAAATCA GAAAGTTTGG ACAGCTTTAC 2850 AAGTATTAGT GCATGCTCAG AACAGGTGGGACTAAAACAA ACTCAAGGAA 2900 CTGTTGGCTG TTTTCCCGAT ACTGAGAATT CAACAGCTCCAGAGCAGAAG 2950 CCACAGGGGC ATAGCTTAGT CCAAACTGCT AATTTCATTT TACAGTGTAT3000 GTAACGCTTA GTCTCACAGT GTCTTTAACT CATCTTTGCA ATCAACAACT 3050TTACTAGTGA CTTTCTGGAA CAATTTCCTT TCAGGAATAC ATATTCACTG 3100 CTTAGAGGTGACCTTGCCTT AATATATTTG TGAAGTTAAA ATTTTAAAGA 3150 TAGCTCATGA AACTTTTGCTTAAGCAAAAA GAAAACCTCG AATTGAAATG 3200 TGTGAGGCAA ACTATGCATG GGAATAGCTTAATGTGAAGA TAATCATTTG 3250 GACAACTCAA ATCCATCAAC ATGACCAATG TTTTTCATCTGCCACATCTC 3300 AAAATAAAAC TTCTGGTGAA ACAAATTAAA CAAAATATCC AAACCTCAAA3350 AAAAA 3355 491 amino acids Amino Acid Linear 4 Met Lys Thr Phe ThrTrp Thr Leu Gly Val Leu Phe Phe Leu Leu 1 5 10 15 Val Asp Thr Gly HisCys Arg Gly Gly Gln Phe Lys Ile Lys Lys 20 25 30 Ile Asn Gln Arg Arg TyrPro Arg Ala Thr Asp Gly Lys Glu Glu 35 40 45 Ala Lys Lys Cys Ala Tyr ThrPhe Leu Val Pro Glu Gln Arg Ile 50 55 60 Thr Gly Pro Ile Cys Val Asn ThrLys Gly Gln Asp Ala Ser Thr 65 70 75 Ile Lys Asp Met Ile Thr Arg Met AspLeu Glu Asn Leu Lys Asp 80 85 90 Val Leu Ser Arg Gln Lys Arg Glu Ile AspVal Leu Gln Leu Val 95 100 105 Val Asp Val Asp Gly Asn Ile Val Asn GluVal Lys Leu Leu Arg 110 115 120 Lys Glu Ser Arg Asn Met Asn Ser Arg ValThr Gln Leu Tyr Met 125 130 135 Gln Leu Leu His Glu Ile Ile Arg Lys ArgAsp Asn Ser Leu Glu 140 145 150 Leu Ser Gln Leu Glu Asn Lys Ile Leu AsnVal Thr Thr Glu Met 155 160 165 Leu Lys Met Ala Thr Arg Tyr Arg Glu LeuGlu Val Lys Tyr Ala 170 175 180 Ser Leu Thr Asp Leu Val Asn Asn Gln SerVal Met Ile Thr Leu 185 190 195 Leu Glu Glu Gln Cys Leu Arg Ile Phe SerArg Gln Asp Thr His 200 205 210 Val Ser Pro Pro Leu Val Gln Val Val ProGln His Ile Pro Asn 215 220 225 Ser Gln Gln Tyr Thr Pro Gly Leu Leu GlyGly Asn Glu Ile Gln 230 235 240 Arg Asp Pro Gly Tyr Pro Arg Asp Leu MetPro Pro Pro Asp Leu 245 250 255 Ala Thr Ser Pro Thr Lys Ser Pro Phe LysIle Pro Pro Val Thr 260 265 270 Phe Ile Asn Glu Gly Pro Phe Lys Asp CysGln Gln Ala Lys Glu 275 280 285 Ala Gly His Ser Val Ser Gly Ile Tyr MetIle Lys Pro Glu Asn 290 295 300 Ser Asn Gly Pro Met Gln Leu Trp Cys GluAsn Ser Leu Asp Pro 305 310 315 Gly Gly Trp Thr Val Ile Gln Lys Arg ThrAsp Gly Ser Val Asn 320 325 330 Phe Phe Arg Asn Trp Glu Asn Tyr Lys LysGly Phe Gly Asn Ile 335 340 345 Asp Gly Glu Tyr Trp Leu Gly Leu Glu AsnIle Tyr Met Leu Ser 350 355 360 Asn Gln Asp Asn Tyr Lys Leu Leu Ile GluLeu Glu Asp Trp Ser 365 370 375 Asp Lys Lys Val Tyr Ala Glu Tyr Ser SerPhe Arg Leu Glu Pro 380 385 390 Glu Ser Glu Phe Tyr Arg Leu Arg Leu GlyThr Tyr Gln Gly Asn 395 400 405 Ala Gly Asp Ser Met Met Trp His Asn GlyLys Gln Phe Thr Thr 410 415 420 Leu Asp Arg Asp Lys Asp Met Tyr Ala GlyAsn Cys Ala His Phe 425 430 435 His Lys Gly Gly Trp Trp Tyr Asn Ala CysAla His Ser Asn Leu 440 445 450 Asn Gly Val Trp Tyr Arg Gly Gly His TyrArg Ser Lys His Gln 455 460 465 Asp Gly Ile Phe Trp Ala Glu Tyr Arg GlyGly Ser Tyr Ser Leu 470 475 480 Arg Ala Val Gln Met Met Ile Lys Pro IleAsp 485 490 491 1780 base pairs Nucleic Acid Single Linear 5 GGCTCAGAGGCCCCACTGGA CCCTCGGCTC TTCCTTGGAC TTCTTGTGTG 50 TTCTGTGAGC TTCGCTGGATTCAGGGTCTT GGGCATCAGA GGTGAGAGGG 100 TGGGAAGGTC CGCCGCGATG GGGAAGCCCTGGCTGCGTGC GCTACAGCTG 150 CTGCTCCTGC TGGGCGCGTC GTGGGCGCGG GCGGGCGCCCCGCGCTGCAC 200 CTACACCTTC GTGCTGCCCC CGCAGAAGTT CACGGGCGCT GTGTGCTGGA250 GCGGCCCCGC ATCCACGCGG GCGACGCCCG AGGCCGCCAA CGCCAGCGAG 300CTGGCGGCGC TGCGCATGCG CGTCGGCCGC CACGAGGAGC TGTTACGCGA 350 GCTGCAGAGGCTGGCGGCGG CCGACGGCGC CGTGGCCGGC GAGGTGCGCG 400 CGCTGCGCAA GGAGAGCCGCGGCCTGAGCG CGCGCCTGGG CCAGTTGCGC 450 GCGCAGCTGC AGCACGAGGC GGGGCCCGGGGCGGGCCCGG GGGCGGATCT 500 GGGGGCGGAG CCTGCCGCGG CGCTGGCGCT GCTCGGGGAGCGCGTGCTCA 550 ACGCGTCCGC CGAGGCTCAG CGCGCAGCCG CCCGGTTCCA CCAGCTGGAC600 GTCAAGTTCC GCGAGCTGGC GCAGCTCGTC ACCCAGCAGA GCAGTCTCAT 650CGCCCGCCTG GAGCGCCTGT GCCCGGGAGG CGCGGGCGGG CAGCAGCAGG 700 TCCTGCCGCCACCCCCACTG GTGCCTGTGG TTCCGGTCCG TCTTGTGGGT 750 AGCACCAGTG ACACCAGTAGGATGCTGGAC CCAGCCCCAG AGCCCCAGAG 800 AGACCAGACC CAGAGACAGC AGGAGCCCATGGCTTCTCCC ATGCCTGCAG 850 GTCACCCTGC GGTCCCCACC AAGCCTGTGG GCCCGTGGCAGGATTGTGCA 900 GAGGCCCGCC AGGCAGGCCA TGAACAGAGT GGAGTGTATG AACTGCGAGT950 GGGCCGTCAC GTAGTGTCAG TATGGTGTGA GCAGCAACTG GAGGGTGGAG 1000GCTGGACTGT GATCCAGCGG AGGCAAGATG GTTCAGTCAA CTTCTTCACT 1050 ACCTGGCAGCACTATAAGGC GGGCTTTGGG CGGCCAGACG GAGAATACTG 1100 GCTGGGCCTT GAACCCGTGTATCAGCTGAC CAGCCGTGGG GACCATGAGC 1150 TGCTGGTTCT CCTGGAGGAC TGGGGGGGCCGTGGAGCACG TGCCCACTAT 1200 GATGGCTTCT CCCTGGAACC CGAGAGCGAC CACTACCGCCTGCGGCTTGG 1250 CCAGTACCAT GGTGATGCTG GAGACTCTCT TTCCTGGCAC AATGACAAGC1300 CCTTCAGCAC CGTGGATAGG GACCGAGACT CCTATTCTGG TAACTGTGCC 1350CTGTACCAGC GGGGAGGCTG GTGGTACCAT GCCTGTGCCC ACTCCAACCT 1400 CAACGGTGTGTGGCACCACG GCGGCCACTA CCGAAGCCGC TACCAGGATG 1450 GTGTCTACTG GGCTGAGTTTCGTGGTGGGG CATATTCTCT CAGGAAGGCC 1500 GCCATGCTCA TTCGGCCCCT GAAGCTGTGACTCTGTGTTC CTCTGTCCCC 1550 TAGGCCCTAG AGGACATTGG TCAGCAGGAG CCCAAGTTGTTCTGGCCACA 1600 CCTTCTTTGT GGCTCAGTGC CAATGTGTCC CACAGAACTT CCCACTGTGG1650 ATCTGTGACC CTGGGCGCTG AAAATGGGAC CCAGGAATCC CCCCCGTCAA 1700TATCTTGGCC TCAGATGGCT CCCCAAGGTC ATTCATATCT CGGTTTGAGC 1750 TCATATCTTATAATAACACA AAGTAGCCAC 1780 470 amino acids Amino Acid Linear 6 Met GlyLys Pro Trp Leu Arg Ala Leu Gln Leu Leu Leu Leu Leu 1 5 10 15 Gly AlaSer Trp Ala Arg Ala Gly Ala Pro Arg Cys Thr Tyr Thr 20 25 30 Phe Val LeuPro Pro Gln Lys Phe Thr Gly Ala Val Cys Trp Ser 35 40 45 Gly Pro Ala SerThr Arg Ala Thr Pro Glu Ala Ala Asn Ala Ser 50 55 60 Glu Leu Ala Ala LeuArg Met Arg Val Gly Arg His Glu Glu Leu 65 70 75 Leu Arg Glu Leu Gln ArgLeu Ala Ala Ala Asp Gly Ala Val Ala 80 85 90 Gly Glu Val Arg Ala Leu ArgLys Glu Ser Arg Gly Leu Ser Ala 95 100 105 Arg Leu Gly Gln Leu Arg AlaGln Leu Gln His Glu Ala Gly Pro 110 115 120 Gly Ala Gly Pro Gly Ala AspLeu Gly Ala Glu Pro Ala Ala Ala 125 130 135 Leu Ala Leu Leu Gly Glu ArgVal Leu Asn Ala Ser Ala Glu Ala 140 145 150 Gln Arg Ala Ala Ala Arg PheHis Gln Leu Asp Val Lys Phe Arg 155 160 165 Glu Leu Ala Gln Leu Val ThrGln Gln Ser Ser Leu Ile Ala Arg 170 175 180 Leu Glu Arg Leu Cys Pro GlyGly Ala Gly Gly Gln Gln Gln Val 185 190 195 Leu Pro Pro Pro Pro Leu ValPro Val Val Pro Val Arg Leu Val 200 205 210 Gly Ser Thr Ser Asp Thr SerArg Met Leu Asp Pro Ala Pro Glu 215 220 225 Pro Gln Arg Asp Gln Thr GlnArg Gln Gln Glu Pro Met Ala Ser 230 235 240 Pro Met Pro Ala Gly His ProAla Val Pro Thr Lys Pro Val Gly 245 250 255 Pro Trp Gln Asp Cys Ala GluAla Arg Gln Ala Gly His Glu Gln 260 265 270 Ser Gly Val Tyr Glu Leu ArgVal Gly Arg His Val Val Ser Val 275 280 285 Trp Cys Glu Gln Gln Leu GluGly Gly Gly Trp Thr Val Ile Gln 290 295 300 Arg Arg Gln Asp Gly Ser ValAsn Phe Phe Thr Thr Trp Gln His 305 310 315 Tyr Lys Ala Gly Phe Gly ArgPro Asp Gly Glu Tyr Trp Leu Gly 320 325 330 Leu Glu Pro Val Tyr Gln LeuThr Ser Arg Gly Asp His Glu Leu 335 340 345 Leu Val Leu Leu Glu Asp TrpGly Gly Arg Gly Ala Arg Ala His 350 355 360 Tyr Asp Gly Phe Ser Leu GluPro Glu Ser Asp His Tyr Arg Leu 365 370 375 Arg Leu Gly Gln Tyr His GlyAsp Ala Gly Asp Ser Leu Ser Trp 380 385 390 His Asn Asp Lys Pro Phe SerThr Val Asp Arg Asp Arg Asp Ser 395 400 405 Tyr Ser Gly Asn Cys Ala LeuTyr Gln Arg Gly Gly Trp Trp Tyr 410 415 420 His Ala Cys Ala His Ser AsnLeu Asn Gly Val Trp His His Gly 425 430 435 Gly His Tyr Arg Ser Arg TyrGln Asp Gly Val Tyr Trp Ala Glu 440 445 450 Phe Arg Gly Gly Ala Tyr SerLeu Arg Lys Ala Ala Met Leu Ile 455 460 465 Arg Pro Leu Lys Leu 470 33base pairs Nucleic Acid Single Linear 7 GCTGACGAAC CAAGGCAACT ACAAACTCCTGGT 33 41 base pairs Nucleic Acid Single Linear 8 TGCGGCCGGA CCAGTCCTCCATGGTCACCA GGAGTTTGTA G 41 33 base pairs Nucleic Acid Single Linear 9GGTGGTGAAC TGCTTGCCGT TGTGCCATGT AAA 33 29 base pairs Nucleic AcidSingle Linear 10 CAGGTTATCC CAGAGATTTA ATGCCACCA 29 34 base pairsNucleic Acid Single Linear 11 TTGGTGGGAG AAGTTGCCAG ATCAGGTGGT GGCA 3425 base pairs Nucleic Acid Single Linear 12 TTCACACCAT AACTGCATTG GTCCA25 34 base pairs Nucleic Acid Single Linear 13 ACGTAGTTCC AGTATGGTGTGAGCAGCAAC TGGA 34 26 base pairs Nucleic Acid Single Linear 14AGTCCAGCCT CCACCCTCCA GTTGCT 26 25 base pairs Nucleic Acid Single Linear15 CCCCAGTCCT CCAGGAGAAC CAGCA 25 2042 base pairs Nucleic Acid SingleLinear 16 GCGGACGCGT GGGTGAAATT GAAAATCAAG ATAAAAATGT TCACAATTAA 50GCTCCTTCTT TTTATTGTTC CTCTAGTTAT TTCCTCCAGA ATTGATCAAG 100 ACAATTCATCATTTGATTCT CTATCTCCAG AGCCAAAATC AAGATTTGCT 150 ATGTTAGACG ATGTAAAAATTTTAGCCAAT GGCCTCCTTC AGTTGGGACA 200 TGGTCTTAAA GACTTTGTCC ATAAGACGAAGGGCCAAATT AATGACATAT 250 TTCAAAAACT CAACATATTT GATCAGTCTT TTTATGATCTATCGCTGCAA 300 ACCAGTGAAA TCAAAGAAGA AGAAAAGGAA CTGAGAAGAA CTACATATAA350 ACTACAAGTC AAAAATGAAG AGGTAAAGAA TATGTCACTT GAACTCAACT 400CAAAACTTGA AAGCCTCCTA GAAGAAAAAA TTCTACTTCA ACAAAAAGTG 450 AAATATTTAGAAGAGCAACT AACTAACTTA ATTCAAAATC AACCTGAAAC 500 TCCAGAACAC CCAGAAGTAACTTCACTTAA AACTTTTGTA GAAAAACAAG 550 ATAATAGCAT CAAAGACCTT CTCCAGACCGTGGAAGACCA ATATAAACAA 600 TTAAACCAAC AGCATAGTCA AATAAAAGAA ATAGAAAATCAGCTCAGAAG 650 GACTAGTATT CAAGAACCCA CAGAAATTTC TCTATCTTCC AAGCCAAGAG700 CACCAAGAAC TACTCCCTTT CTTCAGTTGA ATGAAATAAG AAATGTAAAA 750CATGATGGCA TTCCTGCTGA ATGTACCACC ATTTATAACA GAGGTGAACA 800 TACAAGTGGCATGTATGCCA TCAGACCCAG CAACTCTCAA GTTTTTCATG 850 TCTACTGTGA TGTTATATCAGGTAGTCCAT GGACATTAAT TCAACATCGA 900 ATAGATGGAT CACAAAACTT CAATGAAACGTGGGAGAACT ACAAATATGG 950 TTTTGGGAGG CTTGATGGAG AATTTTGGTT GGGCCTAGAGAAGATATACT 1000 CCATAGTGAA GCAATCTAAT TATGTTTTAC GAATTGAGTT GGAAGACTGG1050 AAAGACAACA AACATTATAT TGAATATTCT TTTTACTTGG GAAATCACGA 1100AACCAACTAT ACGCTACATC TAGTTGCGAT TACTGGCAAT GTCCCCAATG 1150 CAATCCCGGAAAACAAAGAT TTGGTGTTTT CTACTTGGGA TCACAAAGCA 1200 AAAGGACACT TCAACTGTCCAGAGGGTTAT TCAGGAGGCT GGTGGTGGCA 1250 TGATGAGTGT GGAGAAAACA ACCTAAATGGTAAATATAAC AAACCAAGAG 1300 CAAAATCTAA GCCAGAGAGG AGAAGAGGAT TATCTTGGAAGTCTCAAAAT 1350 GGAAGGTTAT ACTCTATAAA ATCAACCAAA ATGTTGATCC ATCCAACAGA1400 TTCAGAAAGC TTTGAATGAA CTGAGGCAAT TTAAAGGCAT ATTTAACCAT 1450TAACTCATTC CAAGTTAATG TGGTCTAATA ATCTGGTATA AATCCTTAAG 1500 AGAAAGCTTGAGAAATAGAT TTTTTTTATC TTAAAGTCAC TGTCTATTTA 1550 AGATTAAACA TACAATCACATAACCTTAAA GAATACCGTT TACATTTCTC 1600 AATCAAAATT CTTATAATAC TATTTGTTTTAAATTTTGTG ATGTGGGAAT 1650 CAATTTTAGA TGGTCACAAT CTAGATTATA ATCAATAGGTGAACTTATTA 1700 AATAACTTTT CTAAATAAAA AATTTAGAGA CTTTTATTTT AAAAGGCATC1750 ATATGAGCTA ATATCACAAC TTTCCCAGTT TAAAAAACTA GTACTCTTGT 1800TAAAACTCTA AACTTGACTA AATACAGAGG ACTGGTAATT GTACAGTTCT 1850 TAAATGTTGTAGTATTAATT TCAAAACTAA AAATCGTCAG CACAGAGTAT 1900 GTGTAAAAAT CTGTAATACAAATTTTTAAA CTGATGCTTC ATTTTGCTAC 1950 AAAATAATTT GGAGTAAATG TTTGATATGATTTATTTATG AAACCTAATG 2000 AAGCAGAATT AAATACTGTA TTAAAATAAG TTCGCTGTCTTT 2042 460 amino acids Amino Acid Linear 17 Met Phe Thr Ile Lys Leu LeuLeu Phe Ile Val Pro Leu Val Ile 1 5 10 15 Ser Ser Arg Ile Asp Gln AspAsn Ser Ser Phe Asp Ser Leu Ser 20 25 30 Pro Glu Pro Lys Ser Arg Phe AlaMet Leu Asp Asp Val Lys Ile 35 40 45 Leu Ala Asn Gly Leu Leu Gln Leu GlyHis Gly Leu Lys Asp Phe 50 55 60 Val His Lys Thr Lys Gly Gln Ile Asn AspIle Phe Gln Lys Leu 65 70 75 Asn Ile Phe Asp Gln Ser Phe Tyr Asp Leu SerLeu Gln Thr Ser 80 85 90 Glu Ile Lys Glu Glu Glu Lys Glu Leu Arg Arg ThrThr Tyr Lys 95 100 105 Leu Gln Val Lys Asn Glu Glu Val Lys Asn Met SerLeu Glu Leu 110 115 120 Asn Ser Lys Leu Glu Ser Leu Leu Glu Glu Lys IleLeu Leu Gln 125 130 135 Gln Lys Val Lys Tyr Leu Glu Glu Gln Leu Thr AsnLeu Ile Gln 140 145 150 Asn Gln Pro Glu Thr Pro Glu His Pro Glu Val ThrSer Leu Lys 155 160 165 Thr Phe Val Glu Lys Gln Asp Asn Ser Ile Lys AspLeu Leu Gln 170 175 180 Thr Val Glu Asp Gln Tyr Lys Gln Leu Asn Gln GlnHis Ser Gln 185 190 195 Ile Lys Glu Ile Glu Asn Gln Leu Arg Arg Thr SerIle Gln Glu 200 205 210 Pro Thr Glu Ile Ser Leu Ser Ser Lys Pro Arg AlaPro Arg Thr 215 220 225 Thr Pro Phe Leu Gln Leu Asn Glu Ile Arg Asn ValLys His Asp 230 235 240 Gly Ile Pro Ala Glu Cys Thr Thr Ile Tyr Asn ArgGly Glu His 245 250 255 Thr Ser Gly Met Tyr Ala Ile Arg Pro Ser Asn SerGln Val Phe 260 265 270 His Val Tyr Cys Asp Val Ile Ser Gly Ser Pro TrpThr Leu Ile 275 280 285 Gln His Arg Ile Asp Gly Ser Gln Asn Phe Asn GluThr Trp Glu 290 295 300 Asn Tyr Lys Tyr Gly Phe Gly Arg Leu Asp Gly GluPhe Trp Leu 305 310 315 Gly Leu Glu Lys Ile Tyr Ser Ile Val Lys Gln SerAsn Tyr Val 320 325 330 Leu Arg Ile Glu Leu Glu Asp Trp Lys Asp Asn LysHis Tyr Ile 335 340 345 Glu Tyr Ser Phe Tyr Leu Gly Asn His Glu Thr AsnTyr Thr Leu 350 355 360 His Leu Val Ala Ile Thr Gly Asn Val Pro Asn AlaIle Pro Glu 365 370 375 Asn Lys Asp Leu Val Phe Ser Thr Trp Asp His LysAla Lys Gly 380 385 390 His Phe Asn Cys Pro Glu Gly Tyr Ser Gly Gly TrpTrp Trp His 395 400 405 Asp Glu Cys Gly Glu Asn Asn Leu Asn Gly Lys TyrAsn Lys Pro 410 415 420 Arg Ala Lys Ser Lys Pro Glu Arg Arg Arg Gly LeuSer Trp Lys 425 430 435 Ser Gln Asn Gly Arg Leu Tyr Ser Ile Lys Ser ThrLys Met Leu 440 445 450 Ile His Pro Thr Asp Ser Glu Ser Phe Glu 455 460

1. An isolated nucleic acid molecule encoding a mammalian TIE ligand,(a) selected from the group consisting of human NL-1 (SEQ. ID. NO: 2),human NL-5 (SEQ. ID. NO: 4), human NL8 (SEQ. ID. NO: 6), and homologsthereof in a non-human mammalian species; or (b) a biologically activefunctional derivative thereof, provided that if the functionalderivative is an amino acid sequence variant, it has at least about 90%sequence identify with the fibrinogen-like domain of a human NL-1, humanNL-5 or human NL8 ligand.
 2. The isolated nucleic acid molecule of claim1 which comprises the coding region of SEQ. ID. NO: 1; SEQ. ID. NO: 3;or SEQ. ID. NO:
 5. 3. The isolated nucleic acid molecule of claim 1which comprises the fibrinogen-like domain of SEQ. ID. NO: 1; SEQ. ID.NO:3; or SEQ. ID. NO:
 5. 4. A vector which comprises a nucleic acidmolecule of claim
 1. 5. A recombinant host cell transformed with anucleic acid molecule according to claim
 1. 6. The recombinant host cellof claim 5 which is a prokaryotic cell.
 7. The recombinant host cell ofclaim 5 which is a eukaryotic cell.
 8. An isolated mammalian TIE ligand,(a) selected from the group consisting of human NL-1 (SEQ. ID. NO: 2),human NL-5 (SEQ. ID NO: 4), human NL8 (SEQ. ID. NO: 6), and homologsthereof in a non-human mammalian species; or (b) a biologically activefunctional derivative thereof, provided that if the functionalderivative is an amino acid sequence variant, it has at least about 90%sequence identity with the fibrinogen-like region of a human NL-1, humanNL-5 or human NL-8 ligand.
 9. An antibody which specifically binds theTIE ligand according to claim
 8. 10. The antibody of claim 9 which is amonoclonal antibody.
 11. The antibody of claim 10 which is an antagonistof the TIE-2 receptor.
 12. The antibody of claim 10 which is an agonistof the TIE-2 receptor.
 13. A composition comprising a TIE ligandaccording to claim 8 or an antibody according to claim 9, in associationwith a carrier.
 14. A conjugate comprising a TIE ligand according toclaim 8 or an antibody according to claim 9, fused to a furthertherapeutic or cytotoxic agent.
 15. The conjugate of claim 14 whereinthe further therapeutic agent is a toxin, another TIE ligand, or amember of the vascular endothelial growth factor (VEGF) family.
 16. Amethod for identifying a cell expressing a TIE receptor comprisingcontacting the cell with a detectably labeled TIE ligand according toclaim 8 under conditions permitting the binding of said TIE ligand tothe TIE receptor, and monitoring the binding.
 17. A method foridentifying an antagonist of a TIE receptor, comprising contacting cellsexpressing the TIE receptor with a TIE ligand according to claim 8 and atest compound, under conditions permitting the binding of said TIEligand to the TIE receptor, and determining whether the test compound iscapable of interfering with the binding of the TIE ligand to the TIEreceptor.
 18. A method for imaging the presence of antiogenesis, whichcomprises administering to a patient a detectably labeled TIE ligandaccording to claim 8, or antibody agonist according to claim 9 of a TIEreceptor, and monitoring angiogenesis.
 19. A method for inhibitingvasculogenesis, comprising administering to a patient an effectiveamount of a TIE ligand according to claim
 8. 20. The method of claim 19wherein said TIE ligand is a native human NL8 molecule.
 21. A method ofinhibiting tumor growth, comprising administering to a patient aneffective amount of a TIE ligand according to claim
 8. 22. A method forpromoting bone development, maturation or growth, comprisingadministering to a patient in need an effective amounf of TIE ligandaccording to claim 8.